

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Cohort Profile: "The Czech Brain Aging Study (CBAS) – prospective multicenter cohort study on risk and protective factors for dementia in the Czech Republic"

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030379
Article Type:	Cohort profile
Date Submitted by the Author:	11-Mar-2019
Complete List of Authors:	Sheardova, Katerina; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice u svate Anny v Brne, NEUROLOGY DEPARTMENT Vyhnaek, Martin; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Nedelska, Zuzana; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Laczo, Jan; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Andel, Ross; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; University of South Florida, School of Aging Studies Marciniak, Rafal; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center Cerman, Jiri; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Lerch, Ondrej; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Hort, Jakub; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology
Keywords:	Dementia < NEUROLOGY, EPIDEMIOLOGY, MENTAL HEALTH

SCHOLARONE™
Manuscripts

1
2
3 **Cohort Profile: “The Czech Brain Aging Study (CBAS) – prospective multicenter cohort**
4 **study on risk and protective factors for dementia in the Czech Republic”**
5
6
7

8
9 Katerina Sheardova^{1,2} *, Martin Vyhnalek^{1,3}, Zuzana Nedelska^{1,3}, Jan Laczo^{1,3}, Ross Andel^{1,4},
10
11 Rafal Marciniak^{1,2}, Jiri Cerman^{1,3}, Ondrej Lerch^{1,3}, Jakub Hort^{1,3}
12
13

14
15 ¹International Clinical Research Center, St. Anne’s University Hospital, Brno, Czech
16
17 Republic
18

19
20 ²Department of Neurology, St. Anne’s University Hospital, Brno, Czech Republic
21

22
23 ³Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and
24
25 Motol University Hospital, Prague, Czech Republic
26

27
28 ⁴School of Aging Studies, University of South Florida, Tampa, USA
29
30
31
32

33 Corresponding author:
34

35 Katerina Sheardova, MD,
36

37 International Clinical Research Center
38

39 Fakultní nemocnice u Svaté Anny v Brně
40

41 Pekarska 53, 656 91 Brno, Czech Republic
42

43 e-mail.: ksheardova@gmail.com
44

45
46
47 Phone: +420603198029
48
49
50
51

52
53 Word count 3103
54
55
56
57
58
59
60

ABSTRACT

Purpose: To alleviate dementia prevalence globally, novel diagnostic methods need to be implemented to allow accurate early diagnosis. Another important effort is to identify demographic, physical/physiological, lifestyle, and genetic factors which contribute to the onset of dementia and Alzheimer disease specifically. The Czech Brain Aging Study (CBAS), is the first large, prospective study to address these issues in Eastern Europe by enrolling a large number of non-demented adults 55+ collecting a variety of personal and biological measures, and tracking cognitive function of the participants over time.

Participants: The recruitment is performed at Brno and Prague University Hospitals. Between January/2011-December/2018, 1228 participants entered CBAS with annual follow up. At each visit, socioeconomic data, family, personal and pharmacological history are collected. Neurology examination, neuropsychology, laboratory, vital sign assessment and MRI are performed. Multiple lifestyle and subjective cognitive complaint questionnaires are administered. In a subset, biomarker assessment (CSF, amyloid PET) and experimental psychology is performed.

Findings to date: Participants had a mean age of 69.7 (\pm 8.1), mean years of education 14.6 (\pm 3.3) at baseline and 59% were women. By the end of 2018, 31% of participants finished 3 and more years of follow up, 9% converted to dementia. APOE status is available from 95% of participants. Biological sample bank linked to CBAS database contains CSF, serum and DNA. Data collected so far have spurred 160 publications.

Future plans: Recruitment is on-going being co-funded by European Regional Development Fund and Ministry of Education of the Czech Republic. Longitudinal data analyses are currently being conducted. CBAS represents a unique effort to study cognitive and brain ageing in Central and Eastern Europe. Proposals for collaboration on specific data from the

1
2
3 database or biospecimen are welcome as well as collaborations with similar cohort studies to
4
5 increase sample size. The details on CBAS are accessible on www.cbas.cz.
6
7
8
9

10 Key words: dementia, epidemiology, mental health
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STRENGTHS AND LIMITATIONS OF THE STUDY:

- CBAS is a prospective cohort collecting longitudinal data on cognitive and brain aging combining prospective data on lifestyle, genetic, neuropsychological, social, physical and biological factors as predictors of cognitive decline in the context of AD biomarkers. All these data are connected to biobank with DNA, CSF and serum which can provide new insights into disease mechanisms and prevention
- The cohort reflects the real clinical population in a national healthcare system where everybody is insured and has an equal access to healthcare.
- CBAS has the potential to serve as a crucial, comprehensive source of information about markers of cognitive decline and impairment and can represent a model for studying risk/protective factors for AD in other Central and Eastern European countries
- Limits are provided by the specifics of Czech health care system, which is similar to Central and Eastern Europe, but different compared to US health care or UK health care. Many parallels with Western European countries.
- The weaknesses include the lack of population-based recruitment into CBAS and a current lack of biomarkers for a large proportion of participants with subjective memory complaints and for cognitively normal controls.

INTRODUCTION

A gradual increase in the prevalence of dementia has been one of the trends accompanying the growth in life expectancy seen across the globe over the past few decades. Dementia affects 1% of those 60 to 65 years of age and about 45% of those aged 90–95 years[1-3].

However, there is also evidence suggesting that the occurrence of dementia has slightly decreased in the last decade (data from England[4] and Stockholm[5]). These data, currently

1
2
3 available only from several countries, suggest a possible effect of treatment of hypertension
4 and diabetes as well as greater attention to lifestyle factors stemming from the increasing
5 awareness of its impact on cognitive and overall health among the general public. Currently,
6 the course of dementia can only be modified by symptomatic therapies and no causal
7 treatment neither for its most common form Alzheimer disease (AD), nor for other
8 neurodegenerative disorders, is available. A crucial step in an effective management of
9 dementia including AD is to better understand the underlying neuropathological mechanisms,
10 differences in ethnic and lifestyle risk factors. To alleviate dementia prevalence on the global
11 level substantially, beyond the modest improvements seen recently, novel diagnostic methods
12 need to be implemented to define the risk factors for conversion from preclinical to early
13 symptomatic (prodromal) stage and further to dementia. Presumably, an early, accurate
14 diagnosis is a crucial, yet still elusive, step in the pursuit of effective treatments for dementia.
15 Another important effort in this context involves the identification of the extent to which
16 demographic, physical/physiological, lifestyle, and genetic factors contribute to the onset of
17 dementia and AD specifically.

18
19 The Czech Brain Aging Study (CBAS), is the first large, prospective study to address these
20 issues in Eastern Europe. CBAS was designed to study potential early biomarkers and
21 risk/protective factors of cognitive decline and dementia by enrolling a large number of older
22 adults, collecting a variety of information about personal and family history, past and current
23 lifestyle, genetic, physical and biological measures, and tracking cognitive function and status
24 and brain MRI of the participants over time. Czech Republic (CR) has approximately 150 000
25 people with dementia per 10.6 million inhabitants. In CR, prodromal stages of the disease are
26 mostly handled by neurologists, who tend to employ more sophisticated diagnostic tools in
27 differential diagnosis of dementia. Geriatricians and psychiatrists usually diagnose and treat
28 patients at the stage of full-blown dementia[6]. Building on this clinical model, CBAS
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 incorporates two independent clinical sites: Memory clinics based at university hospitals in
4
5 Prague and Brno. Data collection started 2005 in Prague and the extension to a multicentric
6
7 design was possible in 2011 thanks to the European Union Regional Development Fund. The
8
9 main aim of both memory clinics is to diagnose and treat neurological disorders that lead to
10
11 cognitive disorders and dementia. Both centers are harmonized in terms of the
12
13 neuropsychological battery, multimodality magnetic resonance imaging (MRI), PET imaging,
14
15 genetic testing, blood tests and cerebrospinal fluid (CSF) analysis and they use the same
16
17 questionnaires and participant database system.
18
19

20
21 The primary objectives of CBAS are: 1. Exploring epidemiological risk factors for cognitive
22
23 decline and dementia in the Czech population; 2. Evaluation of spatial navigation and other
24
25 experimental neuropsychological tests as early markers of AD pathology; 3. Defining
26
27 structural, metabolic and functional biomarkers of neurodegenerative diseases in older adults;
28
29 and 4. Utilizing non-pharmacological interventions in prevention of cognitive decline.
30
31
32

33 **COHORT DESCRIPTION**

34 **Settings**

35
36 CBAS is a prospective longitudinal memory clinic based multi-center study recruiting non-
37
38 demented adults 55+ years of age. Both CBAS centers work as a low threshold facility; hence
39
40 the participants are mostly volunteers who come as a self-referral with memory complaints
41
42 expressed by themselves or the family or were referred by general practitioners, local
43
44 specialists or Czech Alzheimer Society to one of the memory clinics. Cognitively healthy
45
46 controls are recruited by advertising among healthy geriatric population.
47
48
49

50 **Eligibility Criteria**

51
52 All subjects undergo standardized 1.5T or 3T MRI, neuropsychological protocol including
53
54 Uniform Data Set (UDS)[7,8] battery and neurological examination. Standard criteria-based
55
56 consensual diagnosis classifies subjects as cognitively normal controls (NC), subjective
57
58
59
60

1
2
3 cognitive decline (SCD), mild cognitive impairment (MCI) or dementia. NC are defined as
4 subjects with no objective cognitive deficit and no significant subjective cognitive complaints
5 verified by memory complaints questionnaires and structured clinical interview. Subjects
6 referred for newly developed cognitive complaints in which no objective cognitive deficit is
7 found are categorized as SCD. Patients with MCI are diagnosed and classified based on
8 Albert's NIA-AA guidelines 2011[9]. Classification of MCI etiology is based on biomarkers.
9
10 All non-demented subjects aged 55 and older who are classified as NC, SCD or MCI are
11 initially offered to participate in the CBAS. About 95% of these subjects agreed to enter the
12 study. Control participants with no cognitive complaints are recruited from adults taking
13 continuing education classes under the University of the Third Age at Charles University, 2nd
14 Medical Faculty, and from relatives of employees or of the study participants. Written
15 informed consent was obtained from each participant prior entering the database. The Ethics
16 Committee of Motol University Hospital and St. Anne's University Hospital approved the
17 research study.

18
19 The additional exclusion criteria are severe depression (a recent bout of mild depression is not
20 an exclusion criterion) or other neurological or psychiatric disorder or systemic condition
21 potentially causing cognitive impairment. Subjects with a history of stroke are excluded.

22
23 Aside from the CBAS cohort defined as above, baseline data are available from 155 Brno/
24 283 Prague subjects who did not meet the CBAS inclusion criteria labelled as cohort "CBAS
25 Plus"- i.e. patients with mild dementia of various neurodegenerative origin, depression,
26 history of stroke etc. Dementia etiology (AD dementia, frontotemporal lobar degeneration,
27 Parkinsonian syndromes, vascular disorders etc.) is diagnosed according to appropriate
28 guidelines[10,11]. CBAS Plus cohort reflects real memory clinic patient profile and therefore
29 can provide clinically relevant and important research data about wide spectrum of
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

neurological brain diseases leading to dementia and the role of vascular risk factors and psychiatric co-morbidity.

Cohort Characteristics

Between January 2011- December 2018, 1228 subjects who fulfilled the CBAS criteria agreed to enter the study with the contribution of 496 from Brno and 732 from Prague. The basic characteristics of this cohort are presented in table 1, the frequency of vascular risk factors in figure 1. Apolipoprotein E4 (APOE 4) is the strongest genetic risk factor for late onset AD, and is associated with impairments in cerebral metabolism and cerebrovascular function. About 30% of the participants carry at least one APOE 4 allele, the frequency of APOE 4 according to baseline diagnosis is presented in figure 2. About 25% of the subjects are living alone and the rest are living with spouse friend, or a family member. Marital status distribution among the participants see in figure 3.

Table 1. The basic characteristics of the CBAS cohort at baseline

	Total	SCD	MCI	NC
No. of participants	1228	428	732	68
Gender (M/F)	502/726	146/282	329/403	27/41
Age/years	69.7 (8.1)	67.1 (7.9)	71.2 (7.9)	68.9 (7.1)
Education/years	14.6 (3.3)	15.2 (3.0)	14.2 (3.4)	15.9 (3.2)
Depression (GDS score)	3.1 (3.1)	2.9 (3.0)	3.3 (3.2)	1.6 (2.1)

Follow up

Participants are examined annually; they are invited for a follow-up via a letter mailed to their permanent address. Subsets of SCDs and NC who are cognitively stable for the first 3 visits are followed up biannually. At the baseline as well as at each follow-up visit, all participants undergo a comprehensive multidisciplinary examination. Consensual diagnosis is performed based on each visit. Progression from NC/SCD to MCI or to dementia, and from MCI to dementia is the main outcome, along with longitudinal quantitative measures of cognitive performance, which are used for evaluation of early markers of AD and risk factors for

1
2
3 progression. Participants are censored when they progress to dementia as ascertained by panel
4
5 consensus conference. Between entering the study and the end of 2018, 31% of the
6
7 participants completed at least 3 assessments (baseline + 2 follow up visits), 9% converted to
8
9 dementia and 16% were lost to follow up. The recruitment is still on going.

12 **Methods**

14 At each visit, all study participants undergo a standard set of procedures. Neurological and
15
16 comprehensive neuropsychology examination, laboratory and vital functions assessments are
17
18 performed. Socio-demographic data, personal, pharmacological and family history is
19
20 obtained. Participants and their informers complete multiple questionnaires about cognitive
21
22 complaints and lifestyle factors. 1.5T or 3T MRI scans are performed every 24 months and
23
24 when a participant converts to dementia or progresses towards cognitive impairment at an
25
26 unusual rate. Volumetric MRI is analyzed in all patients to obtain measures of regional
27
28 cortical thickness and subcortical volumes cross-sectionally and longitudinally using
29
30 Freesurfer image analysis suite (v5.3; <http://surfer.nmr.mgh.harvard.edu/>). The details of
31
32 Freesurfer image processing have been published elsewhere[12-17], including previous
33
34 studies by our group[18,19]. A subset of MRI volumes has been previously measured using
35
36 manual tracing and a subset of participants' MRI volumes is used to measure the atrophy of
37
38 cholinergic basal forebrain nuclei[20,21]. Genotyping is carried out at baseline. In a subset,
39
40 CSF and/or amyloid PET is performed and additional data are collected from experimental
41
42 neuropsychology, spatial navigation and personality trait assessment. The detailed procedures
43
44 are presented in Supplementary table S1.

46
47
48 The CBAS is complemented by a biological sample bank linked to the data from the CBAS
49
50 and "CBAS Plus" cohorts. The CSF collection and storage are carried out after signing an
51
52 informed consent in accordance with the ethical guidelines in the CR and good clinical
53
54 practice, and according to the widely recognized consensus protocol for the standardization of
55
56
57
58
59
60

cerebrospinal fluid collection and biobanking [22]. 18 aliquots of 0.2ml CSF and 5-9 aliquots of serum are stored for each participant. All samples are stored at -80C. Commercial ELISA kits (Innogenetics) are used for dementia biomarker analyses (A β 1-42, protein tau, and phospho-tau) and cut off values derived from validation study are used[23]. The characteristics of the biobank as of December 2018 are listed in table 2.

Table 2. Biobank characteristics

	Aliquots stored at -80C	No. of participants
CSF	18x0.2ml	75 Brno/350 Prague
Serum	5-9x0.5ml	145 Brno/350 Prague
DNA	concentration >100 ng/ μ l	95% of all participants

Patient and public involvement

Patient involvement was crucial in questionnaire implementation. Initial versions of questionnaires were largely consulted with a pilot group of patients. Their caregivers and their remarks and feedback were considered when making the final version to ensure better understanding and participation. Wider public engagement is ensured by public lectures regularly performed by the CBAS team members, informing about the study, its meaning and procedures; partial results concerning lifestyle are discussed. The information about the study and possibility to join is communicated to public via various channels: Concept Alzheimer Café, CBAS webpage, we also closely cooperate with Czech Alzheimer Association (CAA) connecting dementia specialists with patients and their caregivers. Many CAA layperson members and participants of the study helped to disseminate the baseline information which helped to strengthen the recruitment.

FINDINGS TO DATE

The CBAS medical and non-medical personnel participate in academic and research activities. Data collected so far have spurred more than 160 publications, primarily in impacted neurology and neuroscience journals. We highlight the most significant ones here.

Spatial navigation as an early marker of AD

Our unique assessment instrument, the real-space human analogue of the Morris water maze called the Blue velvet arena, plus its computerized equivalent, test separately the hippocampal-dependent allocentric and the parietal lobe-dependent egocentric types of navigation[24]. Results so far have demonstrated that the tool, especially its component testing allocentric navigation, may serve as an important early marker of cognitive impairment and AD[25]. In the scope of CBAS we have demonstrated a strong association between real-space and computer-based versions of this test, which further shifts the importance of our research towards the routine clinical use[26]. The relationship between spatial navigation and brain structures in patients with mild AD dementia and amnesic MCI (aMCI) was investigated in our other studies. In the first study, we demonstrated a direct relation between right hippocampal volume and allocentric navigation above and beyond total brain and left hippocampal volumes in real-space and computer-based versions of the test[18]. In another study, we demonstrated a direct relationship between basal forebrain volume and allocentric navigation above and beyond hippocampal volume, again in both versions of the test[20]. Together, these findings provide physiological evidence for the internal validity of the spatial navigation test.

We have also demonstrated that spatial navigation performance in aMCI patients is influenced by their genetic background. We showed that spatial navigation deteriorates in a dose-dependent manner as a function of APOE $\epsilon 4$ status[27] and that especially allocentric navigation is impaired in individuals with APOE $\epsilon 3/\epsilon 3$ (AD risk neutral) genotype, who carry TOMM40 "523" VL variants[28]. Our findings thus indicate that spatial navigation performance can identify aMCI patients at an increased genetic risk for AD. Spatial navigation has potential not only in early and differential diagnostics, but also as an outcome measure to evaluate treatment effect[29]. In addition, we have linked cardiovascular biomarkers, namely

1
2
3 elevated homocysteine and total cholesterol levels to spatial navigation deficits in our recent
4
5 study[30].
6
7

8 Our other studies have found that, besides the egocentric and allocentric types of navigation,
9
10 navigation without vision (path integration) and perspective taking also identify patients with
11
12 mild AD dementia and aMCI among a general sample[31,32]. In sum, spatial navigation is a
13
14 promising psychological marker of early AD, which may be distinguished from other cognitive
15
16 functions, and thus its assessment is likely to contribute important information to a
17
18 comprehensive neuropsychological profile[33].
19
20
21

22 **Experimental neuropsychology helping to find patients at early stage of AD**

23
24
25 In the scope of examination of the affected medial temporal structures we have used “in-house”
26
27 developed Familiar Landmarks identification test together with the validated Facial Emotion
28
29 Recognition and Identification of Familiar Faces tests[34,35]. We suggested that recognition of
30
31 different categories of objects might reflect different stages of AD pathology from
32
33 transentorhinal cortex through amygdala to fusiform gyrus as it is described in
34
35 neuropathological studies[36,37].
36
37
38

39 We have also tested the specificity of several standard memory tests for reflecting hippocampal
40
41 atrophy in non-demented geriatric population. The Enhanced Cued Recall test with controlled
42
43 encoding and cued recall, designed to detect hippocampal dysfunction, did not exceed the
44
45 standard memory tests. In the non-demented population we therefore did not confirm the
46
47 hypothesis of greater selectivity of the tests with controlled encoding and cued recall paradigm
48
49 to detect the damage of hippocampus. The result has immediate implications for clinical
50
51 practice [38]. Initial longitudinal data analyses are currently being conducted.
52
53
54
55

56 **STRENGTHS AND LIMITATIONS**

57
58
59
60

1
2
3 CBAS represents a unique effort to study cognitive and brain ageing in Central and Eastern
4 Europe. It is a prospective cohort, based in a relatively culturally and genetically homogenous
5 Czech population. The location of the two CBAS centers in the two main regions of the CR
6 (Bohemia and Moravia) allows to cover practically the whole country. To our best knowledge
7 it is the first and only coordinated clinically based study collecting longitudinal data on
8 cognitive and brain aging combining prospective data on lifestyle, genetic,
9 neuropsychological, social, physical and biological factors as predictors of cognitive decline
10 in the context of AD biomarkers in CR and Eastern Europe and among a few studies globally.
11 The weaknesses include the lack of population-based recruitment into CBAS; the current lack
12 of biomarkers for a large proportion of participants with subjective memory complaints and
13 for cognitively normal controls; and the lack of information regarding those who refused to
14 participate. However, the cohort reflects the real clinical population in a national healthcare
15 system where everybody is insured and has an equal access to healthcare.
16
17 In conclusion, CBAS has the potential to serve as a crucial, comprehensive source of
18 information about markers of cognitive decline and impairment and can represent a model for
19 studying risk/protective factors for AD in other Central and Eastern European countries.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **COLLABORATION**

42
43
44 We have established a cohort which allows for integration of multiple clinical data with
45 biomarkers and lifestyle factors. All these data are connected to biobank with DNA, CSF and
46 serum which can provide new insights into disease mechanisms and prevention. The details
47 about the study are accessible on www.cbас.cz. We encourage collaborations with researchers
48 from other cohort studies with similar aspects to increase sample size.
49
50
51
52
53
54
55
56
57
58
59
60
Proposals for collaboration on specific data from the database or biospecimen (DNA, CSF,
serum) are welcome. All proposals for specific analyses are reviewed by a scientific

1
2
3 committee. For more information, please contact the corresponding author and/or the
4
5 Principal Investigator through email: sheardova@fnusa.cz, jakub.hort@fnmotol.cz
6
7

8 9 **Acknowledgement:**

10
11
12 All of the CBAS participants and their relatives are appreciated for their involvement in the
13
14 project and their dedication.

15
16 We would like to thank the heads of Neurology departments Prof. Petr Marusic from Motol
17
18 University Hospital Prague and Prof. Milan Brazdil from St. Anne's University Hospital Brno
19
20 for their support. Big appreciation to the supporting CBAS team: neurologists and
21
22 psychologists, for thorough data collection, study nurses and coordinators for an excellent
23
24 management of participants and procedures and also to external collaborators: Jitka
25
26 Hanzalova Motol University Hospital, Prague, for laboratory assessment, Vaclav Matoska
27
28 from Homolka Hospital, Prague and T. Freiburger from Cardiovascular and Transplant
29
30 surgery Center Brno for covering the DNA biobank, T. Machulka and S. Belaskova from
31
32 ICRC Brno for database and statistic support. We would also like to thank the teams from
33
34 MRI and PET facilities from University Hospitals in Brno and Prague.
35
36
37
38

39
40 **Funding:** During 2011-2015, CBAS was supported by the project FNUSA-ICRC [grant
41
42 number CZ.1.05/1.1.00/02.0123] from the European Regional Development Fund. Between
43
44 2016-2020, it is supported by National Program of Sustainability II (Ministry of Education,
45
46 Youth and Sports of the Czech Republic) [grant number LQ1605].
47
48

49
50 The following grants contributed to specific subprojects based on CBAS: Ministry of Health
51
52 Internal Grant Agency [grant number NT 11225-4/2010], Czech Health Research Council
53
54 [grant numbers 16-27611A, NV18-04-00455], Motol University Hospital, Prague, Czech
55
56 Republic [grant number CZ – DRO 00064203], Institutional Support of Laboratory Research
57
58 [grant number 2/2012 (699002)], Institutional Support of Excellence 2nd Medical Faculty
59
60

1
2
3 Charles University [grant number 699012], Grant Agency of the Czech Republic [grant
4 numbers 309/05/0693, 309/09/1053] and Grant Agency of the Charles University [grant
5 numbers 91007, 74308, 98509, 624012, 546113, 1108214, 135215, 654217, 308216, 546317
6 and 693018].
7
8
9

10 11 12 **References**

- 13
14
15
16 1 Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration
17 of the literature. *Acta Psychiatr Scand* 1987;76(5):465–479. doi: 10.1111/j.1600-
18 0447.1987.tb02906.x
19
20
21
22 2 Kukull WA, Ganguli M. Epidemiology of dementia: concepts and overview. *Neurol Clin*
23 2000;18(4):923–950. DOI: 10.1016/S0733-8619(05)70233-4
24
25
26
27 3 Boller F, Grafman J. Handbook of Neuropsychology. Amsterdam: Elsevier 2001.
28
29
30 4 Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of
31 dementia in individuals aged 65 years and older from three geographical areas of England:
32 results of the Cognitive Function and Ageing Study I and II. *Lancet* 2013;382(9902):1405–
33 1412. doi: 10.1016/S0140-6736(13)61570-6
34
35
36
37 5 Qiu C, von Strauss E, Bäckman L, et al. Twenty-year changes in dementia occurrence
38 suggest decreasing incidence in central Stockholm, Sweden. *Neurology* 2013;80(20):1888–
39 1894. doi: 10.1212/WNL.0b013e318292a2f9
40
41
42
43
44
45 6 Sheardova K, Hort J, Rektorova I, et al. Dementia Diagnosis and Treatment in Czech
46 Neurological and Psychiatric Practices. *Cesk Slov Neurol N* 2012;75(2):208–211.
47
48
49
50 7 Weintraub S, Salmon D, Mercaldo N, et al. The Alzheimer's Disease Centers' Uniform Data
51 Set (UDS): the neuropsychologic test battery. *Alzheimer Dis Assoc Disord* 2009;23(2):91–
52 101. doi: 10.1097/WAD.0b013e318191c7dd
53
54
55
56
57
58
59
60

- 1
2
3 8 Nikolai T, Stepankova H, Kopecek M, et al. The Uniform Data Set, Czech Version:
4 Normative Data in Older Adults from an International Perspective. *J Alzheimers Dis*
5
6 2018;61(3):1233–1240. doi: 10.3233/JAD-170595
7
8
9
10 9 Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due
11 to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's
12 Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*
13
14 2011;7(3):270–279. doi: 10.1016/j.jalz.2011.03.008
15
16
17
18
19 10 Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS Guidelines on the diagnosis and
20 management of disorders associated with dementia. *Eur J Neurol* 2012;19(9):1159–79. doi:
21
22 10.1111/j.1468-1331.2012.03784.x
23
24
25
26 11 Ressner P, Hort J, Rektorova I, et al. Recommendations for the diagnosis and management
27 of Alzheimer's disease and other disorders associated with dementia. *Cesk Slov Neurol N*
28
29 2008;71(4): 494–501.
30
31
32
33 12 Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis: I. Segmentation and
34 surface reconstruction. *Neuroimage* 1999;9(2):179–194. doi: 10.1006/nimg.1998.0395
35
36
37
38 13 Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic
39 resonance images. *Proc Natl Acad Sci U S A* 2000;97(20):11050–11055. doi:
40
41 10.1073/pnas.200033797
42
43
44 14 Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the
45 human cerebral cortex on MRI scans into gyral based regions of interest. *Neuroimage*
46
47 2006;31(3):968–980. doi: 10.1016/j.neuroimage.2006.01.021
48
49
50
51 15 Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of
52 neuroanatomical structures in the human brain. *Neuron* 2002;33(3):341–355. doi:
53
54 10.1016/S0896-6273(02)00569-X
55
56
57
58
59
60

- 1
2
3 16 Fischl B, Salat DH, van der Kouwe AJ, et al. Sequence-independent segmentation of
4 magnetic resonance images. *Neuroimage* 2004;23(Suppl 1):S69-S84. doi:
5
6 10.1016/j.neuroimage.2004.07.016
7
8
9
10 17 Reuter M, Schmansky NJ, Rosas HD, et al. Within-subject template estimation for
11 unbiased longitudinal image analysis. *Neuroimage* 2012;61(4):1402–1418. doi:
12
13 10.1016/j.neuroimage.2012.02.084
14
15
16
17 18 Nedelska Z, Andel R, Laczo J, et al. Spatial navigation impairment is proportional to right
18 hippocampal volume. *Proc Natl Acad Sci U S A* 2012;109(7):2590–2594. doi:
19
20 10.1073/pnas.1121588109
21
22
23
24 19 Horinek D, Petrovicky P, Hort J, et al. Amygdalar volume and psychiatric symptoms in
25 Alzheimer's disease: an MRI analysis. *Acta Neurol Scand* 2006;113(1):40–45. doi:
26
27 10.1111/j.1600-0404.2006.00540.x
28
29
30
31 20 Kerbler GM, Nedelska Z, Fripp J, et al. Basal Forebrain Atrophy Contributes to
32 Allocentric Navigation Impairment in Alzheimer's Disease Patients. *Front Aging Neurosci*
33 2015;7:185. doi: 10.3389/fnagi.2015.00185
34
35
36
37 21 Kerbler GM, Fripp J, Rowe CC, et al. Basal forebrain atrophy correlates with amyloid β
38 burden in Alzheimer's disease. *Neuroimage Clin* 2014;7:105–113. doi:
39
40 10.1016/j.nicl.2014.11.015.
41
42
43
44 22 Vanderstichele H, Bibl M, Engelborghs S, et al. Standardization of preanalytical aspects of
45 cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper
46 from the Alzheimer's Biomarkers Standardization Initiative. *Alzheimers Dement*
47 2012;8(1):65–73. doi: 10.1016/j.jalz.2011.07.004
48
49
50
51
52
53 23 Hort J, Glosova L, Vyhnalek M, et al. The liquor tau protein and beta amyloid in
54 Alzheimer's disease. *Cesk Slov Neurol N* 2007;70(1):30–36.
55
56
57
58
59
60

- 1
2
3 24 Hort J, Laczó J, Vyhnalek M, et al. Spatial navigation deficit in amnesic mild cognitive
4 impairment. *Proc Natl Acad Sci U S A* 2007;104(10):4042–4047. doi:
5
6 10.1073/pnas.0611314104
7
8
9
10 25 Laczó J, Vlcek K, Vyhnalek M, et al. Spatial navigation testing discriminates two types of
11 amnesic mild cognitive impairment. *Behav Brain Res* 2009;202(2):252–259. doi:
12
13 10.1016/j.bbr.2009.03.041
14
15
16
17 26 Laczó J, Andel R, Vyhnalek M, et al. From morris water maze to computer tests in the
18 prediction of Alzheimer's disease. *Neurodegener Dis* 2012;10(1–4):153–157. doi:
19
20 10.1159/000333121
21
22
23
24 27 Laczó J, Andel R, Vyhnalek M, et al. APOE and spatial navigation in amnesic MCI:
25 results from a computer-based test. *Neuropsychology* 2014;28(5):676–684. doi:
26
27 10.1037/neu0000072
28
29
30
31 28 Laczó J, Andel R, Vyhnalek M, et al. The effect of TOMM40 on spatial navigation in
32 amnesic mild cognitive impairment. *Neurobiol Aging* 2015;36(6):2024–2033. doi:
33
34 10.1016/j.neurobiolaging.2015.03.004
35
36
37
38 29 Hort J, Andel R, Mokrisova I, et al. Effect of Donepezil in Alzheimer Disease Can Be
39 Measured by a Computerized Human Analog of the Morris Water Maze. *Neurodegener Dis*
40 2014;13(2–3):192–196. doi: 10.1159/000355517
41
42
43
44 30 Parizkova M, Andel R, Lerch O, et al. Homocysteine and Real-Space Navigation
45 Performance among Non-Demented Older Adults. *J Alzheimers Dis* 2017;55(3):951–964. doi:
46
47 10.3233/JAD-160667
48
49
50
51 31 Mokrisova I, Laczó J, Andel R, et al. Real-space path integration is impaired in
52 Alzheimer's disease and mild cognitive impairment. *Behav Brain Res* 2016;307:150–158. doi:
53
54 10.1016/j.bbr.2016.03.052
55
56
57
58
59
60

- 1
2
3 32 Markova H, Laczó J, Andel R, et al. Perspective taking abilities in amnesic mild cognitive
4 impairment and Alzheimer's disease. *Behav Brain Res* 2015;281:229–238. doi:
5
6 10.1016/j.bbr.2014.12.033
7
8
9
10 33 Laczó J, Andel R, Nedelska Z, et al. Exploring the contribution of spatial navigation to
11 cognitive functioning in older adults. *Neurobiol Aging* 2017;51:67–70.
12
13 10.1016/j.neurobiolaging.2016.12.003
14
15
16
17 34 Ekman P, Friesen WV. Pictures of Facial Affect. Palo Alto: Consulting Psychologists
18 Press 1976.
19
20
21 35 Keane J, Calder AJ, Hodges JR, et al. Face and emotion processing in frontal variant
22 frontotemporal dementia. *Neuropsychologia* 2002;40(6):655–665. doi: 10.1016/S0028-
23 3932(01)00156-7
24
25
26
27
28 36 Sheardova K, Laczó J, Vyhnalek M, et al. Famous landmark identification in amnesic
29 mild cognitive impairment and Alzheimer's disease. *PLoS One* 2014;9(8). doi:
30 10.1371/journal.pone.0105623
31
32
33
34
35 37 Varjassyová A, Hořínek D, Andel R, et al. Recognition of Facial Emotional Expression in
36 Amnesic Mild Cognitive Impairment. *J Alzheimers Dis* 2013;33(1):273–280. doi:
37 10.3233/JAD-2012-120148
38
39
40
41
42 38 Vyhnalek M, Nikolai T, Andel R, et al. Neuropsychological Correlates of Hippocampal
43 Atrophy in Memory Testing in Nondemented Older Adults. *J Alzheimers Dis* 2014;42(Suppl
44 3):S81–S90. doi: 10.3233/JAD-132642
45
46
47
48
49 39 Nelson HE. The National Adult Reading Test (NART): test manual. Windsor: NFER-
50 Nelson 1982.
51
52
53
54 40 Topinková E, Jiráček R, Kožený J. Krátká neurokognitivní baterie pro screening demence v
55 klinické praxi: sedmiminutový screeningový test. *Neurol. pro Praxi* 2002;6: 323–328.
56
57
58
59
60

- 1
2
3 41 Bezdicek O, Stepankova H, Moták L, et al. Czech version of Rey Auditory Verbal
4 Learning test: normative data. *Neuropsychol Dev Cogn B Aging Neuropsychol Cogn*
5
6 2014;21(6):693–721. doi: 10.1080/13825585.2013.865699
7
8
9
10 42 Benedict RHB, Schretlen D, Groninger L, et al. Revision of the brief visuospatial memory
11 test: Studies of normal performance, reliability, and validity. *Psychological Assessment*
12
13 1996;8(2):145–153. doi: 10.1037/1040-3590.8.2.145
14
15
16
17 43 Meyers JE, Meyers KR. Rey Complex Figure Test and Recognition Trial: Professional
18 manual. Odessa, FL: Psychological Assessment Resources 1995.
19
20
21 44 Bezdicek O, Lukavsky J, Stepankova H, et al. The Prague Stroop Test: Normative
22 standards in older Czech adults and discriminative validity for mild cognitive impairment in
23 Parkinson's disease. *J Clin Exp Neuropsychol* 2015;37(8):794–807. doi:
24
25 10.1080/13803395.2015.1057106
26
27
28
29
30 45 Wechsler D. WAIS-III - Wechslerova inteligenční škála pro dospělé. Praha: Hogrefe–
31 Testcentrum 2010.
32
33
34
35 46 Loonstra AS, Tarlow AR, Sellers AH. COWAT metanorms across age, education, and
36 gender. *Appl Neuropsychol* 2001;8(3):161–166. doi: 10.1207/S15324826AN0803_5
37
38
39
40 47 Mazancova AF, Nikolai T, Stepankova H, et al. The Reliability of Clock Drawing Test
41 Scoring Systems Modeled on the Normative Data in Healthy Aging and Nonamnesic Mild
42 Cognitive Impairment. *Assessment* 2017;24(7):945–957. doi: 10.1177/1073191116632586
43
44
45
46 48 Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules.
47 *Neurology* 1993;43:2412-2414. doi: 10.1212/WNL.43.11.2412-a
48
49
50
51 49 Pfeffer RI, Kurosaki TT, Harrah CH, et al. Measurement of functional activities in older
52 adults in the community. *J Gerontol* 1982;37(3): 323–329. doi: 10.1093/geronj/37.3.323
53
54
55
56
57
58
59
60

- 1
2
3 50 Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric
4 depression screening scale: a preliminary report. *J Psychiatr Res* 1983;17(1):37–49. doi:
5
6 10.1016/0022-3956(82)90033-4
7
8
9
10 51 Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety:
11 psychometric properties. *J Consult Clin Psychol* 1988;56(6): 893–897. doi: 10.1037/0022-
12
13 006X.56.6.893
14
15
16
17 52 Thomas-Antérion C, Ribas C, Honoré-Masson S, et al. Le questionnaire de plainte
18 mnésique (QPC): un outil de recherche de plainte suspecte d'évoquer une maladie
19 d'Alzheimer. *L'Année Gérontologique* 2003;17(1):56–65.
20
21
22
23
24 53 Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual
25 physical activity in epidemiological studies. *Am J Clin Nutr* 1982;36(5):936–42. doi:
26
27 10.1093/ajcn/36.5.936
28
29
30
31 54 Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness
32 scale. *Sleep* 1991;14(6):540–545. doi: 10.1093/sleep/14.6.540
33
34
35
36 55 Reguli Z, Svobodová L. Czech version of the diagnosis of fear of falls in seniors - FES-I
37 (Falls Efficacy Scale International). *Studia Sportiva* 2011;5(2):5–12.
38
39
40
41 56 Papp KV, Amariglio RE, Dekhytar M, et al. Development of a psychometrically
42 equivalent short form of the Face-Name Associative Memory Exam for use along the early
43 Alzheimer's disease trajectory. *Clin Neuropsychol* 2014;28(5):771–785. doi:
44
45 10.1080/13854046.2014.911351
46
47
48
49 57 Buschke H, Mowrey WB, Ramratan WS, et al. Memory Binding Test Distinguishes
50 Amnesic Mild Cognitive Impairment and Dementia from Cognitively Normal Elderly. *Arch*
51
52
53
54
55
56 58 Holden HM, Hoebel C, Loftis K, et al. Spatial pattern separation in cognitively normal
57 young and older adults. *Hippocampus* 2012;22(9):1826–1832. doi: 10.1002/hipo.22017
58
59
60

1
2
3 59 Vlček K, Laczó J, Vajnerová O, et al. Spatial navigation and episodic-memory tests in
4 screening of dementia. *Psychiatrie* 2006;10:35–38.

5
6
7 60 Marková H, Laczó J, Andel R, et al. Perspective taking abilities in amnesic mild cognitive
8 impairment and Alzheimer's disease. *Behav Brain Res* 2015;281:229–38. doi:
9
10
11
12 10.1016/j.bbr.2014.12.033

13
14 61 Gomez R, Fisher JW. Domains of spiritual well-being and development and validation of
15 the Spiritual Well-Being Questionnaire. *Pers Individ Dif* 2003;35(8):1975–1991. doi:
16
17
18
19 10.1016/S0191-8869(03)00045-X

20
21 62 OPD Working Group. Operationalized Psychodynamic Diagnostics: Foundations and
22 Manual. Hogrefe & Huber Pub 2001.

23
24
25 63 Wechsler D. WMS–IIIa - Wechslerova zkrácená paměťová škála. Praha: Hogrefe –
26
27
28
29 Testcentrum 2011.


30 **Figure legends:**

31
32
33 Figure 1 The frequency of vascular risk factors in CBAS cohort

34
35 Figure 2 APOE 4 status according to baseline diagnosis in the CBAS cohort

36
37 Figure 3 Marital status of the CBAS participants
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Vascular risk factors frequency in CBAS cohort (%)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22


APOE 4 frequency according to baseline diagnosis in CBAS cohort (%)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30



For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>
||| APOE 4 heterozygots # APOE 4 homozygots

Marital status of the CBAS participants



■ Married # Divorced ▨ Widowed ■ Single

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

ed from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Supplementary table S1. Procedures performed within the study (frequency is specified)

Frequency	Procedure	Specification
Annually	Clinical exam	Standard complex neurology examination
Annually	Standard neuropsychology	<p>Uniform Data Set[7,8]: MMSE, Digit Span Forward and Backward (WMS-R), Digit Symbol (WAIS-R), Trail Making Test A and B, Animal list generation, Vegetable list generation, Boston Naming Test (30 odd items), Logical Memory, Story A (WMS-R)</p> <p>Premorbid ability estimation: National Adult Reading Test[39]</p> <p>Memory assesment: Enhanced cued recall test[40], Rey Auditory Verbal Learning test[41], Brief Visuospatial Memory Test– Revised[42], Rey-Osterrieth Complex Figure Test – (ROCFT) recall[43]</p> <p>Executive functions: Prague Stroop test[44], Similarities (WAIS-R)[45], Controlled Oral Word Association Test[46]</p> <p>Visuoconstruction: Clock Test[47], ROCFT copy[43]</p> <p>Functional scales: Clinical dementia rating scale[48], Functional assessment questionnaire[49]</p> <p>Symptoms of anxiety and depression: Geriatric depression scale (15 items version)[50], Beck anxiety inventory[51]</p>
Annually	Laboratory	Fasting glucose, lipids, homocysteine, B12, thyroid hormones, folic acid, renal and liver function, CRP, glycosylated haemoglobin
Annually	Vital functions	BMI, blood pressure, pulse, waist/hipps ratio
Annually	Socio- economic data	Marital status, Type of living, Current occupation
Annually	Questionnaires	Subjective cognitive complaints (QPC)[52], physical/mental activity at midlife and now, Becke's Habitual Physical Activity[53], Epworth Sleepiness Scale[54], Falls Self-Efficacy Scale – International[55]
Biannually	MRI	1.5T protocol: plane localizer; standard clinical T2; T1 3-dimensional isometric magnetization-prepared rapid gradient echo(MPRAGE) with isometric voxel;fluid-attenuated inversion recovery(FLAIR); T2*; echoplanar imagingfor diffusion tensor imaging with 32directions.3T protocol: plane localizer; standardclinical T1 and T2; T1

		3-dimensional isometric magnetization-prepared rapid gradient echo (MPRAGE) with isometric voxel; echoplanar imaging for diffusion tensor imaging with 64 directions; fluid-attenuated inversion recovery (FLAIR); T2 fast spin echo; T2*; resting state functional MR imaging. 3T MRI switch since 2013 in Brno, since 2019 in Prague
At baseline	Demography	Age, education, occupation, laterality
At baseline all Optional	Genotyping	APOE TOMM40, BDNF, CD36, BuChE, KIBRA, TREM2, PSEN 1, PSEN 2, APP, TARDBP, MAPT, GRN, C9orf72
Subset at both centres	CSF	Amyloid, tau, ptau, oligoclonal bands, CSF biochemistry,
Subset at both centres	Amyloid PET	PET/MRI or PET/CT (visual assessment), flutemetamol, dual phase (“perfusion”) PET;
Prague cohort all	Spatial navigation[24-26]	hidden goal task, simple navigation task, path integration task, Y-maze assessment, intersections task, sea hero quest, spatial tasks in virtual reality/augmented virtual reality
Prague cohort optional	Experimental neuropsychology	Facial emotion recognition[35], Famous faces identification[34], FNAME 12 items version[56], Memory binding test[57], spatial pattern separation task[58] In house invented - Famous landmarks identification[36], episodic-like memory test[59], Arena Perspective Taking Task[60]
Brno cohort All at baseline	Specific questionnaires	Spiritual well-being questionnaire (SHALOM)[61], Operationalized Psychodynamic Diagnostics OPD-2 (OPD working group)[62], early life trauma assessment

MMSE – Minimal state examination, WMS-R -Wechsler Memory Scale Revised[63],
WAIS-R - Wechsler Adult Intelligence Scale-Revised[45]

BMJ Open

Cohort Profile: "The Czech Brain Aging Study (CBAS) – prospective multicenter cohort study on risk and protective factors for dementia in the Czech Republic"

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030379.R1
Article Type:	Cohort profile
Date Submitted by the Author:	25-Aug-2019
Complete List of Authors:	Sheardova, Katerina; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice u svate Anny v Brne, NEUROLOGY DEPARTMENT Vyhnaek, Martin; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Nedelska, Zuzana; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Laczo, Jan; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Andel, Ross; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; University of South Florida, School of Aging Studies Marciniak, Rafal; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center Cerman, Jiri; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Lerch, Ondrej; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Hort, Jakub; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Mental health, Public health, Neurology
Keywords:	Dementia < NEUROLOGY, EPIDEMIOLOGY, MENTAL HEALTH



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Cohort Profile: “The Czech Brain Aging Study (CBAS) – prospective multicenter cohort**
4 **study on risk and protective factors for dementia in the Czech Republic”**
5
6
7

8
9 Katerina Sheardova^{1,2} *, Martin Vyhnalek^{1,3}, Zuzana Nedelska^{1,3}, Jan Laco^{1,3}, Ross Andel^{1,4},
10
11 Rafal Marciniak^{1,2}, Jiri Cerman^{1,3}, Ondrej Lerch^{1,3}, Jakub Hort^{1,3}
12
13

14
15 ¹International Clinical Research Center, St. Anne’s University Hospital, Brno, Czech
16
17 Republic
18

19 ²Department of Neurology, St. Anne’s University Hospital, Brno, Czech Republic
20

21 ³Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and
22
23 Motol University Hospital, Prague, Czech Republic
24

25
26 ⁴School of Aging Studies, University of South Florida, Tampa, USA
27
28
29
30
31
32

33 Corresponding author:
34

35 Katerina Sheardova, MD,
36

37 International Clinical Research Center
38

39 Fakultní nemocnice u Svaté Anny v Brně
40

41 Pekarska 53, 656 91 Brno, Czech Republic
42

43 e-mail.: ksheardova@gmail.com
44
45

46 Phone: +420603198029
47
48
49
50
51

52 Word count 3785
53
54
55
56
57
58
59
60

ABSTRACT

Purpose: Identification of demographic, physical/physiological, lifestyle, and genetic factors contributing to the onset of dementia specifically, Alzheimer disease (AD), and implementation of novel methods for early diagnosis are important to alleviate prevalence of dementia globally. The Czech Brain Aging Study (CBAS) is the first large, prospective study to address these issues in Central/Eastern Europe by enrolling non-demented adults aged 55+, collecting a variety of personal and biological measures, and tracking their cognitive function over time.

Participants: The CBAS recruitment was initiated in 2011 from memory clinics at Brno and Prague University Hospitals, and by end of 2018, the study included 1228 participants. Annual follow-ups include collection of socioeconomic and personal history, neurology, neuropsychology, laboratory, vital sign assessment and brain MRI. Multiple lifestyle questionnaires are administered. In a subset, biomarker assessment (CSF, amyloid PET) and spatial navigation are performed. Participants are of average age of 69.7 ± 8.1 years and 14.6 ± 3.3 years of education at baseline, and 59% are women. By the end of 2018, 31% finished 3 and more years of follow up, 9% converted to dementia. APOE status is available from 95% of participants. Biological sample bank linked to CBAS database contains CSF, serum and DNA.

Findings to date: Overall, the findings mainly from cross-sectional analyses indicate that spatial navigation is a promising marker of early AD which may be distinguished from other cognitive functions. Specificity of several standard memory tests for early AD pathology was assessed with implications for clinical practice. The relationship of various life-style factors to cognition and brain atrophy was reported.

Future plans: Recruitment is on-going with secured funding. Longitudinal data analyses are currently being conducted. Proposals for collaboration on specific data from the database or

1
2
3 biospecimen are welcome as well as collaborations with similar cohort studies to increase
4
5 sample size. The details are accessible on www.cbass.cz.
6
7
8
9
10
11

12 Key words: dementia, epidemiology, mental health
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STRENGTHS AND LIMITATIONS OF THE STUDY:

- CBAS is a prospective longitudinal study of cognitive and brain aging that combines prospective data on lifestyle, genetic, neuropsychological, social, physical and biological factors with neuropsychological and imaging data in the context of AD biomarkers.
- Although biomarkers are available for most cognitively impaired participants, only a subsample of participants with subjective memory complaints and of cognitively normal controls has biomarkers available.
- Participants come from university hospital-based memory clinics from two major Czech cities—Brno and Prague—which limits generalizability, although universal health care coverage promotes university hospital visits by a more diverse patient population.
- CBAS has the potential to serve as a crucial, comprehensive source of information about markers of cognitive decline and impairment and can represent a model for studying risk/protective factors for AD in other Central and Eastern European countries.

INTRODUCTION

A gradual increase in the prevalence of dementia has been one of the trends accompanying the growth in life expectancy seen across the globe over the past few decades. Dementia affects 1% of those 60 to 65 years of age and about 45% of those aged 90–95 years.[1, 2] However, there is also evidence suggesting that the prevalence as well as incidence of dementia has significantly decreased in the last decade - data from England[3] and Stockholm.[4] These data, currently available only from several countries, suggest a possible effect of treatment of

1
2
3 hypertension and diabetes as well as greater attention to lifestyle factors stemming from the
4 increasing awareness of its impact on cognitive and overall health among the general public.
5
6 Currently, the course of dementia can only be modified by symptomatic therapies and no
7
8 causal treatment for its most common form Alzheimer disease (AD) or for other
9
10 neurodegenerative disorders is available. A crucial step in an effective management of
11
12 dementia including AD is to better understand the underlying neuropathological mechanisms
13
14 and the differences in ethnic and lifestyle risk factors. An important effort in this context
15
16 involves the identification of the extent to which demographic, physical/physiological,
17
18 lifestyle, and genetic factors contribute to the onset of dementia and AD specifically.
19
20 A parallel effort includes early identification of cognitive impairment. To further alleviate
21
22 dementia incidence on the global level, novel diagnostic methods need to be implemented to
23
24 define the risk factors for conversion from preclinical to early symptomatic (prodromal) stage
25
26 and to dementia. Presumably, an early, accurate diagnosis is a crucial, yet still elusive, step in
27
28 the pursuit of effective treatments for dementia.
29
30
31
32
33
34

35 The Czech Brain Aging Study (CBAS) is the first large, prospective study to address these
36
37 issues in Eastern Europe. CBAS was designed to study potential early biomarkers and
38
39 risk/protective factors of cognitive decline and dementia by enrolling a large number of older
40
41 adults, collecting a variety of information about personal and family history, past and current
42
43 lifestyle, genetic, physical and biological measures, and tracking cognitive function and status
44
45 and brain MRI of the participants over time. Czech Republic (CR) has approximately 150,000
46
47 patients with dementia among its roughly 10.6 million inhabitants. CR, like other Eastern
48
49 European countries, is unique in a number of ways including a relatively high prevalence of
50
51 cardiovascular issues. However, since eighties of the 20th century, the frequency of common
52
53 vascular risk factors is continuously decreasing in CR, and the mortality associated with
54
55 vascular risk factors in CR and neighboring countries such as Poland has been significantly
56
57
58
59
60

1
2
3 lower compared to other Eastern European countries, such as Russia. Although the cause of
4 this remains mainly unexplained improved prevention and education are especially
5 suggested.[5, 6] Also a system of health care delivery that favors memory clinic visits from a
6 wide variety of patient population is rather specific. In CR, prodromal stages of the disease
7 are mostly handled by neurologists, whereas post-diagnostic patients are more often seen by
8 geriatricians and psychiatrists.[7] In general, neurologists tend to employ more sophisticated
9 diagnostic tools for detecting early stages of cognitive deficit and assessment of its etiology
10 than psychiatrists/geriatricians.

11
12 Building on this model, CBAS was established using recruitment from two memory clinics at
13 two independent neurology departments based at university hospitals in Prague and Brno,
14 respectively. Data collection started 2005 in Prague and the extension to a multicenter design
15 was possible in 2011 thanks to the European Union Regional Development Fund. The main
16 aim of both memory clinics is to diagnose and treat neurological disorders that lead to
17 cognitive disorders and dementia. Both centers are harmonized in terms of the
18 neuropsychological battery, multimodality magnetic resonance imaging (MRI), PET imaging,
19 genetic testing, blood tests and cerebrospinal fluid (CSF) analysis, the use of questionnaires,
20 and a participant database system.

21
22 Although CBAS lacks the advantages of a population-based study, it uses the only currently
23 feasible design for this type of study in the CR. In addition, it provides access to a relatively
24 large number of clinical patients. A population-based study would need to include much
25 larger numbers to recruit the same number of at-risk patients, which would deem the study not
26 feasible under the current funding mechanisms.

27
28 The overarching objectives of CBAS are to help understand lifestyle, genetic, and biological
29 factors influencing variability in the onset of cognitive impairment including AD and finding
30 novel ways of early AD diagnosis. The specific aims are: 1. Exploring epidemiological risk

1
2
3 factors for cognitive decline and dementia in the Czech Republic; 2. Evaluation of spatial
4 navigation and other experimental neuropsychological tests as early markers of AD
5
6 pathology; 3. Defining structural, metabolic and functional biomarkers of neurodegenerative
7
8 diseases in older adults; and 4. Exploring non-pharmacological interventions in prevention of
9
10 cognitive decline.
11
12
13

14 **COHORT DESCRIPTION**

15 **Settings**

16
17 CBAS is a prospective longitudinal memory clinic based multi-center study recruiting non-
18
19 demented adults 55+ years of age. Both CBAS centers work as a low threshold facility; hence
20
21 the participants are mostly volunteers who come as a self-referral with memory complaints
22
23 expressed by themselves or the family or who were referred by general practitioners, local
24
25 specialists or Czech Alzheimer Society to one of the memory clinics. Cognitively healthy
26
27 controls are recruited by advertising among general older population and including those with
28
29 no cognitive complaints, including participants recruited from adults taking continuing
30
31 education classes under the University of the Third Age at Charles University, 2nd Medical
32
33 Faculty, and from relatives of employees or study participants.
34
35
36
37
38

39 **Eligibility Criteria**

40
41 All participants entering the memory clinics undergo neurological examination, brain CT or
42
43 MRI, and cognitive assessment, excluding subjects with dementia. All non-demented subjects
44
45 aged 55 and older who are able to undergo MRI examination and do not fulfill exclusion
46
47 criteria (see below) are initially offered to participate in the CBAS. About 95% of these
48
49 subjects agreed to enter the study. The additional exclusion criteria are severe depression
50
51 (participants with a recent bout of mild depression are included), a diagnosis of neurological
52
53 or other psychiatric disorder, a systemic condition potentially causing cognitive impairment,
54
55 or a recent history of stroke.
56
57
58
59
60

Written informed consent was obtained from each participant prior entering the database. The Ethics Committee of Motol University Hospital and St. Anne's University Hospital approved the study.

Cohort Characteristics

Between January 2011 and December 2018, 1228 subjects who fulfilled the CBAS criteria agreed to enter the study with the contribution of 496 from Brno and 732 from Prague, with enrollment accelerated more recently. The basic characteristics of this cohort are presented in table 1, the frequency of vascular risk factors is in figure 1. The frequencies of these vascular risk factors in CBAS are similar to national reports and studies, almost solely conducted by cardiologists and internal medicine specialists in CR,[5] although the proportion of smokers is lower in CBAS compared to national average reported in 2004.

Table 1. Basic characteristics of the CBAS cohort at baseline

	Total			SCD			MCI			NC		
	mean (SD) or ratio	median or %	Inter quartile range	mean (SD) or ratio	median or %	Inter quartile range	mean (SD) or ratio	median or %	Inter quartile range	mean (SD) or ratio	median or %	Inter quartile range
No. of participants	1228			428			732			68		
Gender (M/F)	502/726	40.9%M		146/282	34.1%M		329/403	44.9%M		27/41	39.7%M	
Age/years	69.7 (8.0)	70	64-75	67.1 (7.9)	66	61-72	71.2 (7.9)	72	66-77	68.9 (7.1)	69	64-73
Education/years	14.6 (3.3)	14	12-17	15.2 (3.0)	15	13-18	14.3 (3.4)	13	12-17	16.1 (3.4)	16	13-17
Depression (GDS)	3.86 (3.1)	3	2-5	3.9 (3.0)	3	2-5	4.0 (3.2)	3	2-6	1.6 (1.3)	1	0-1

Notes: SCD = subjective cognitive decline; MCI = mild cognitive impairment; SD = standard deviation; GDS = Geriatric Depression Scale[8]

Apolipoprotein E4 (APOE; and its $\epsilon 4$ allele, specifically) is the strongest genetic risk factor for late onset AD, and is associated with impairments in cerebral metabolism and cerebrovascular function. About 30% of the participants carry at least one APOE $\epsilon 4$ allele. The frequency of APOE $\epsilon 4$ allele assessed at baseline was – 15.2% heterozygotes and 5.4% homozygotes in MCI subjects, 7.2% heterozygotes and 2.1% homozygotes in SCD subjects and only 1.2% heterozygotes in NC subjects. About 25% of the subjects are living alone and

1
2
3 the rest are living with a spouse, friend, or a family member. The age of the cohort reflects the
4 age distribution of older adults in the CR, with 12% of the subjects 80+ years of age, and 4%
5 85+ years of age at baseline. There are 3.3 million people aged 55+ living in the CR, 12% of
6 whom are 80+ and 6% are 85+ according to 2018 Czech Census data. Education of our cohort
7 is slightly higher than the average education level of 55+ population in the CR; 7.3% of the
8 CBAS participants finished basic education (vs. 26% in CR), 68% finished secondary (high
9 school) education (vs. 62% in CR) and 48% achieved college/university degree (vs. 9% in
10 CR). Efforts are under way to recruit a more diverse cohort.
11
12
13
14
15
16
17
18
19
20

21 Aside from the CBAS cohort defined above, baseline data are available from 155 Brno/ 283
22 Prague subjects who did not meet the CBAS inclusion criteria under the name “CBAS Plus”-
23 i.e. patients with mild dementia of various neurodegenerative origin, depression, history of
24 stroke etc. Dementia etiology (AD dementia, frontotemporal lobar degeneration, Parkinsonian
25 syndromes, vascular disorders etc.) is diagnosed according to appropriate guidelines.[9]
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

At each visit, all study participants undergo a standard set of procedures. Neurological and comprehensive neuropsychology examination including Uniform Data Set (UDS) battery,[10, 11] laboratory and vital functions assessments are also performed. Socio-demographic, personal, pharmacological and family history data are obtained. Participants and their informants complete multiple questionnaires about cognitive complaints and lifestyle factors. 1.5T or 3T MRI scans are performed every 24 months or earlier when a participant converts to dementia or progresses towards cognitive impairment at an unusual rate. Volumetric MRI is analyzed in all patients to obtain measures of regional cortical thickness and subcortical

volumes cross-sectionally and longitudinally using Freesurfer image analysis suite (v5.3; <http://surfer.nmr.mgh.harvard.edu/>). The details of Freesurfer image processing have been published elsewhere,[12-14] including previous studies by our group.[15, 16] A subset of MRI volumes has been previously measured using manual tracing and a subset of participants' MRI volumes is used to measure the atrophy of cholinergic basal forebrain nuclei.[17] Genotyping is carried out at baseline. In a subset, CSF and/or amyloid PET is performed and additional data are collected from experimental neuropsychology, spatial navigation and personality trait assessment. The detailed procedures including their timelines are presented in table 2.

Table 2. The CBAS Procedures

Frequency	Procedure	Specification
Annually	Clinical exam	Standard complex neurology examination
Annually	Standard neuropsychology	<p>Uniform Data Set[10, 11]: Mini-Mental State Examination, Digit Span Forward and Backward, Digit Symbol, Trail Making Test A and B, Animal list generation, Vegetable list generation, Boston Naming Test (30 odd items), Logical Memory, Story A</p> <p>Premorbid ability estimation: National Adult Reading Test[18]</p> <p>Memory assessment: Enhanced cued recall test,[19] Rey Auditory Verbal Learning Test,[20] Brief Visuospatial Memory Test–Revised,[21] Rey-Osterrieth Complex Figure Test – (ROCFT) recall[22]</p> <p>Executive functions: Prague Stroop test,[23] Similarities (WAIS-R)[24], Controlled Oral Word Association Test[25]</p> <p>Visuoconstruction: Clock Test,[26] ROCFT copy[22]</p> <p>Functional scales: Clinical Dementia Rating scale,[27] Functional assessment questionnaire[28]</p> <p>Symptoms of anxiety and depression: Geriatric Depression Scale (15 items version),[8] Beck Anxiety Inventory[29]</p>
Annually	Laboratory	Fasting glucose, lipid profile, homocysteine, vitamin B12, thyroid hormones, folic acid, renal and liver function, C-reactive protein, glycosylated hemoglobin
Annually	Vital functions	blood pressure, pulse frequency, waist/hips ratio, BMI
Annually	Socio- economic data	Marital status, Type of living, Current occupation
Annually	Questionnaires	Subjective cognitive complaints (QPC),[30] physical/mental activity at midlife and currently, Becke's Habitual Physical

		Activity[31], Epworth Sleepiness Scale,[32] Falls Self-Efficacy Scale – International[33]
Biannually	MRI	1.5T protocol: plane localizer; standard clinical T2; T1 3-dimensional isometric magnetization-prepared rapid gradient echo(MPRAGE) with isometric voxel; fluid-attenuated inversion recovery(FLAIR); T2*; echoplanar imaging for diffusion tensor imaging with 32directions.3T protocol: plane localizer; standard clinical T1 and T2; T1 3-dimensional isometric magnetization-prepared rapid gradient echo (MPRAGE) with isometric voxel; echoplanar imaging for diffusion tensor imaging with 64 directions; fluid-attenuated inversion recovery (FLAIR); T2 fast spin echo;T2*; resting state functional MRI. Switch to 3T MRI since 2015 in Brno, since 2019 in Prague
At baseline	Demography	Age, education, occupation, laterality
At baseline all Optional	Genotyping	APOE TOMM40, BDNF, CD36, BuChE, KIBRA, TREM2, PSEN 1, PSEN 2, APP, TARDBP, MAPT, GRN, C9orf72
Subset at both centres	CSF	Amyloid β -42, total, tau, p-tau, oligoclonal bands, CSF biochemistry,
Subset at both centres	Amyloid PET	PET/MRI or PET/CT (visual assessment), flutemetamol, dual phase (“perfusion”) PET;
Prague cohort all	Spatial navigation[34, 35, 36]	hidden goal task, simple navigation task, path integration task, Y-maze assessment, intersections task, sea hero quest, spatial tasks in virtual reality/augmented virtual reality
Prague cohort optional	Experimental neuropsychology	Facial emotion recognition,[37, 38] Famous faces identification,[38] FNAME 12 items version,[39] Memory binding test,[40] spatial pattern separation task[41] In house developed tests: Famous landmarks identification,[42] episodic-like memory test,[43] Arena Perspective Taking Task[44]
Brno cohort All at baseline	Specific questionnaires	Spiritual well-being questionnaire (SHALOM),[45] Operationalized Psychodynamic Diagnostics OPD-2 (OPD working group),[46] early life trauma assessment

Standard criteria-based consensus diagnosis classifies subjects as cognitively normal controls (NC), subjective cognitive decline (SCD) or mild cognitive impairment (MCI). NC are defined as subjects with no objective cognitive deficit and no significant subjective cognitive complaints verified by memory complaints questionnaires and a structured clinical interview. Subjects referred for newly developed cognitive complaints in which no objective cognitive

deficit is found are categorized as SCD. Patients with MCI are diagnosed and classified based on 2011 NIA-AA guidelines by Albert and colleagues.[47] Classification of MCI etiology is based on biomarkers.

The CBAS is complemented by a biological sample bank linked to data from the CBAS and “CBAS Plus” cohorts. The CSF collection and storage are carried out after signing an informed consent in accordance with the ethical guidelines in the CR and good clinical practice, and according to the widely recognized consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.[48] Eighteen aliquots of 0.2ml CSF and 5-9 aliquots of serum are stored for each participant. All samples are stored at -80C. Commercial ELISA kits (Innogenetics®) are used for dementia biomarker analyses (A β 1-42, protein tau, and phospho-tau) and cut off values derived from validation study are used.[49] The characteristics of the biobank as of December 2018 are listed in table 3.

Table 3. Biobank characteristics

	Aliquots per patient stored at -80C	No. of participants
CSF	18x0.2ml	75 in Brno/350 in Prague
Serum	5-9x0.5ml	145 in Brno/350 in Prague
DNA	concentration >100 ng/ μ l	95% of all participants

Follow-up

Participants are examined annually; they are invited for a follow-up via a letter mailed to their permanent address. Subsets of SCDs and NC who are cognitively stable for the first 3 visits are followed every other year. At each follow-up visit, all participants undergo a standard set of procedures described in the Methods section; see table 2 for additional details. Consensus diagnosis is performed based on each visit. Progression from NC/SCD to MCI or to dementia, and from MCI to dementia is the main outcome, along with longitudinal quantitative measures of cognitive performance, which are used for evaluation of early markers of AD and risk factors for progression. Participants are censored when they progress to dementia as

1
2
3 ascertained by panel consensus conference or if they no longer can undergo an MRI
4
5 examination. Between entering the study and the end of 2018, 31% of the total of 1228
6
7 participants already completed at least 3 full yearly evaluations (baseline + 2 follow up visits)
8
9 with at least 2 brain MRI sessions. 9% from all the participants converted to dementia at
10
11 some timepoint within their follow-up and were no longer followed, and 16% of the
12
13 participants were lost to follow-up for various reasons (loss of interest, newly acquired MRI
14
15 intolerance, worsening health condition, change of residence address not allowing invitation
16
17 for follow up. From all participants recruited by the end of 2018, 931 (75%) continue in the
18
19 follow-up. The recruitment is still ongoing.
20
21
22
23

24 **Patient and public involvement**

25
26 Patient involvement was crucial in questionnaire implementation. Initial versions of
27
28 questionnaires were consulted with a pilot group of patients and their caregivers. Based on
29
30 their feedback, we excluded McNair's questionnaire of activities of daily living. The
31
32 adaptation of Mild Behaviour impairment checklist was graphically reworked after being
33
34 consulted with our participants increasing the rate of successful completion considerably. In
35
36 the tests developed by our team, such as the Famous Landmark Identification Test[42] or the
37
38 Subjective Spatial Memory Complaints Questionnaire,[50] we consulted our participants
39
40 during the entire development process including the selection of relevant items. Some of the
41
42 items were generated from qualitative research which always preceded the development of
43
44 new questionnaires. These procedures ensured high participation and validity.
45
46
47
48

49 Wider public engagement is ensured by public lectures regularly performed by the CBAS
50
51 team members, informing about the study, its meaning and procedures; partial results
52
53 concerning lifestyle are discussed. The information about the study and possibility to join is
54
55 communicated to public via various channels: Concept Alzheimer Café, CBAS webpage, we
56
57 also closely cooperate with Czech Alzheimer Association (CAA) connecting dementia
58
59
60

1
2
3 specialists with patients and their caregivers. Many CAA layperson members and participants
4
5 of the study help disseminate information about the study which facilitates recruitment.
6

7 **FINDINGS TO DATE**

8
9
10 Data collected so far have spurred more than 160 publications mainly from cross-sectional
11
12 analyses, primarily in impacted neurology and neuroscience journals (the complete list is
13
14 available at www.cbass.cz). We highlight the most significant ones here in the context of the
15
16 aims of the study.
17

18 **Early markers of AD**

19 Spatial navigation

20
21
22 Spatial navigation testing is part of baseline CBAS protocol[34, 35] (details see in table 2).
23
24 Outcomes of this comprehensive examination have been compared with results of structural
25
26 brain MRI and genetic and laboratory assessment. Our cross-sectional studies have shown that
27
28 spatial navigation is a distinct cognitive function and a promising cognitive marker of early AD,
29
30 the assessment of which may add important information to a comprehensive
31
32 neuropsychological profile of individuals in the CBAS study[51, 52] and may be useful for
33
34 early and differential diagnosis of AD, or for evaluating the effect of therapies.[36, 53]
35
36
37

38
39 We have demonstrated that impairment of spatial navigation is associated with structural
40
41 changes of the right hippocampus, entorhinal cortex, posterior parietal lobe and basal forebrain,
42
43 i.e. the structures that are impaired very early in AD[15, 17, 51] and that it can be influenced
44
45 by genetic background[54, 55] and cardiovascular risk factors.[56]
46
47

48 Experimental neuropsychology

49
50
51 We have introduced our “in-house” developed Famous Landmarks Identification Test which
52
53 was created with the help of our participants and we have shown that it could be useful for
54
55 recognizing early stages of AD.[42] We have also tested the specificity of several standard
56
57
58
59
60

1
2
3 memory tests for reflecting hippocampal atrophy in the CBAS participants which could have
4 immediate implications for clinical practice.[57]
5
6

7 **Lifestyle factors and AD**

8
9
10 We have recently completed the first longitudinal MRI analysis from CBAS[58] showing that
11 the level of spiritual well-being can influence the atrophy rates in regions affected by AD
12 pathology, associated with attention and with behavioral symptoms. The manuscript is being
13 prepared for publication. Previous studies have included examinations of cholesterol[59] and
14 blood glucose[60] in relation to cognitive outcomes.
15
16

17
18 The recruitment is ongoing with secured funding. We have just reached a sufficient number of
19 longitudinally followed participants to begin with longitudinal data analyses which will
20 contribute significantly to the fulfillment of most of the aims of the study.
21
22

23 **Non-pharmacological interventions**

24
25 We have completed an intervention study with mindfulness-based stress reduction (MBSR)
26 therapy and cognitive training in members of CBAS with MCI. We have shown that MBSR is
27 a suitable intervention for subjects with mild cognitive decline[61] and findings regarding its
28 effect on cognition, immunology profile and depression suggest that MBSR could be effective
29 in secondary prevention. The manuscript is submitted for publication.
30
31

32 **STRENGTHS AND LIMITATIONS**

33
34 CBAS represents a unique effort to study cognitive and brain ageing in Central and Eastern
35 Europe. It is a prospective study of a relatively culturally and genetically homogenous Czech
36 population based mainly on recruitment of volunteers who come to a memory clinic in one of
37 two largest cities in the country-Prague and Brno. The study includes a large biological
38 sample bank (sera, CSF, DNA) that can enhance diagnostic accuracy and improve predictive
39 validity of analyses with other AD risk factors, such as lifestyle factors and vascular risk
40 factors. Despite of several studies on vascular risk factors, it has not been satisfactorily
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 explained yet why is their frequency so high in Eastern Europe and to which extend are they
4 associated with cognitive performance.[62] We believe that data from our study can also
5 contribute to the information about this subject.
6
7

8
9
10 The study also has limitations. While having two sites involved in participant recruitment is
11 an advantage, it cannot compete with a population-based recruitment. Although it is also of
12 note that due to the nature of health care delivery in the CR, attendance of the two memory
13 clinics is far from restricted to the close geographical proximity. Rather, older adults of all
14 ages visit the clinics from a variety of geographical areas. Therefore, coding of participant
15 residence (urban vs rural or by region) can enrich analyses and help increase interpretability
16 of any findings, and potentially ameliorate this limitation to at least some extent. Given the
17 recruitment from university hospital-based clinics, one may assume that the sample could
18 attract relatively young patients.[63] However, although the average age for patients with
19 MCI is substantially lower than the UK-based Cognitive Function & Ageing Studies, it is
20 roughly similar to studies from Italy, Spain, Australia, and studies conducted in Asia.[64]
21
22 Additionally, the current sample is relatively highly educated and efforts are under way to
23 recruit participants with more diverse educational attainment. There are also advantages to
24 basing recruitment on memory clinics. Specifically, this approach allows access to at-risk
25 patients at a much higher rate than a population-based study, making the approach more
26 feasible under the current CBAS funding structure.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 Although brain imaging is available for most participants, biomarkers are available only for a
47 subsample. Efforts are under way to increase biomarker data availability. Detailed
48 information is missing on subjects lost to follow-up. Despite these limitations, to the best of
49 our knowledge, CBAS remains the largest coordinated effort to collect longitudinal data in the
50 context of cognitive and brain aging in the Czech Republic and in Eastern Europe in general.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

1
2
3 neuropsychological, social, physical and biological factors as predictors of cognitive decline
4
5 in the context of AD biomarkers. Until a population-based study with the same aim can be
6
7 carried out within Eastern Europe, the CBAS may serve as the only source of information
8
9 about a wide variety of risk factors for cognitive impairment in this geographical region.

10
11
12 In conclusion, CBAS has the potential to serve as a crucial, comprehensive source of
13
14 information about markers of cognitive decline and impairment and can represent a model for
15
16 studying risk/protective factors for AD in other Central and Eastern European countries.

17 18 **Acknowledgement:**

19
20
21 All of the CBAS participants and their relatives are appreciated for their involvement in the
22
23 project and their dedication.

24
25
26 We would like to thank the heads of Neurology departments Prof. Petr Marusic from Motol
27
28 University Hospital Prague and Prof. Milan Brazdil from St. Anne's University Hospital Brno
29
30 for their support. Big appreciation to the supporting CBAS team: neurologists and
31
32 psychologists, for thorough data collection, study nurses and coordinators for an excellent
33
34 management of participants and procedures and also to external collaborators: Jitka
35
36 Hanzalova Motol University Hospital, Prague, for laboratory assessment, Vaclav Matoska
37
38 from Homolka Hospital, Prague and T. Freiburger from Cardiovascular and Transplant
39
40 surgery Center Brno for covering the DNA biobank, T. Machulka and S. Belaskova from
41
42 ICRC Brno for database and statistic support. We would also like to thank the teams from
43
44 MRI and PET facilities from University Hospitals in Brno and Prague.

45 46 47 **FOOTNOTES:**

48
49
50 **Patient consent for publication:** Not required

51
52
53 **Contributors:** KS, JH, MV, JL and ZN conceived the hypothesis and study design, KS, MV,
54
55 JL, RM, JC, JH collected the data, OL, ZN, RA provided the data analyses, RA is responsible
56
57 for statistical analyses. All authors had input on interpretation and reporting of study findings.
58
59
60

1
2
3 KS wrote the first draft; all authors reviewed and edited the final version. All authors provided
4 approval for the published version of this manuscript.
5

6
7 **Funding:** During 2011-2015, CBAS was supported by the project FNUSA-ICRC [grant
8 number CZ.1.05/1.1.00/02.0123] from the European Regional Development Fund. Between
9 2016-2020, it is supported by National Program of Sustainability II (Ministry of Education,
10 Youth and Sports of the Czech Republic) [grant number LQ1605]. The following grants
11 contributed to specific subprojects based on CBAS: Ministry of Health Internal Grant Agency
12 [grant number NT 11225-4/2010], Czech Health Research Council [grant numbers 16-
13 27611A, NV18-04-00455], Motol University Hospital, Prague, Czech Republic [grant number
14 CZ – DRO 00064203], Institutional Support of Laboratory Research [grant number 2/2012
15 (699002)], Institutional Support of Excellence 2nd Medical Faculty Charles University [grant
16 number 699012], Grant Agency of the Czech Republic [grant numbers 309/05/0693,
17 309/09/1053] and Grant Agency of the Charles University [grant numbers 91007, 74308,
18 98509, 624012, 546113, 1108214, 135215, 654217, 308216, 546317 and 693018].
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 **Competing interests:** None declared.
36

37 **Provenance and peer review:** Not commissioned; externally peer reviewed.
38

39 **Ethics approval:** The Ethics Committee of Motol University Hospital and St. Anne's
40 University Hospital approved the study.
41
42
43

44 **Collaboration:** Proposals for collaboration on specific data from the database or biospecimen
45 (DNA, CSF, serum) are welcome. We have established a cohort which allows for integration
46 of multiple clinical data with biomarkers and lifestyle factors. The details about the study are
47 accessible on www.cbас.cz. We encourage collaborations with researchers from other cohort
48 studies with similar aspects to increase sample size.
49
50
51
52
53
54

55 **Data sharing:** Data are available upon reasonable request. All proposals for specific analyses
56 are reviewed by a scientific committee. Data ownership remains with the center that obtained
57
58
59
60

1
2
3 the data originally. Inquiries about the data sharing from the CBAS database, data re-use or
4
5 biospecimen can be addressed to the corresponding author and/or the Principal Investigator
6
7 through email: sheardova@fnusa.cz, jakub.hort@fnmotol.cz
8
9

10 **References**

- 11
12 1. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative
13
14 integration of the literature. *Acta Psychiatr Scand* 1987;76(5):465–479. doi: 10.1111/j.1600-
15
16 0447.1987.tb02906.x
- 17
18 2. Kukull WA, Ganguli M. Epidemiology of dementia: concepts and overview. *Neurol Clin*
19
20 2000;18(4):923–950. doi: 10.1016/S0733-8619(05)70233-4
- 21
22 3. Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of
23
24 dementia in individuals aged 65 years and older from three geographical areas of England:
25
26 results of the Cognitive Function and Ageing Study I and II. *Lancet* 2013;382(9902):1405–
27
28 1412. doi: 10.1016/S0140-6736(13)61570-6
- 29
30 4. Qiu C, von Strauss E, Bäckman L, et al. Twenty-year changes in dementia occurrence
31
32 suggest decreasing incidence in central Stockholm, Sweden. *Neurology* 2013;80(20):1888–
33
34 1894. doi: 10.1212/WNL.0b013e318292a2f9
- 35
36 5. Cifkova R, Skodova Z. Longitudinal trends in major cardiovascular disease risk factors in
37
38 the Czech population. *Cas Lek Cesk*. 2004;143(4):219-26.
- 39
40 6. Pajak A, Kozela M. Cardiovascular Disease in Central and East Europe. *Public Health*
41
42 *Reviews* 2012; 33(2):416–435. doi: 10.1007/BF03391644
- 43
44 7. Sheardova K, Hort J, Rektorova I, et al. Dementia Diagnosis and Treatment in Czech
45
46 Neurological and Psychiatric Practices. *Cesk Slov Neurol N* 2012;75(2):208–211.
- 47
48 8. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric
49
50 depression screening scale: a preliminary report. *J Psychiatr Res* 1983;17(1):37–49. doi:
51
52 10.1016/0022-3956(82)90033-4
53
54
55
56
57
58
59
60

- 1
2
3 9. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS Guidelines on the diagnosis and
4 management of disorders associated with dementia. *Eur J Neurol* 2012;19(9):1159–79. doi:
5 10.1111/j.1468-1331.2012.03784
6
7
8
9
10 10. Weintraub S, Salmon D, Mercaldo N, et al. The Alzheimer's Disease Centers' Uniform
11 Data Set (UDS): the neuropsychologic test battery. *Alzheimer Dis Assoc Disord*
12 2009;23(2):91–101. doi: 10.1097/WAD.0b013e318191c7dd
13
14
15
16
17 11. Nikolai T, Stepankova H, Kopecek M, et al. The Uniform Data Set, Czech Version:
18 Normative Data in Older Adults from an International Perspective. *J Alzheimers Dis*
19 2018;61(3):1233–1240. doi: 10.3233/JAD-170595
20
21
22
23
24 12. Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the
25 human cerebral cortex on MRI scans into gyral based regions of interest. *Neuroimage*
26 2006;31(3):968–980. doi: 10.1016/j.neuroimage.2006.01.021
27
28
29
30
31 13. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of
32 neuroanatomical structures in the human brain. *Neuron* 2002;33(3):341–355. doi:
33 10.1016/S0896-6273(02)00569-X
34
35
36
37
38 14. Reuter M, Schmansky NJ, Rosas HD, et al. Within-subject template estimation for
39 unbiased longitudinal image analysis. *Neuroimage* 2012;61(4):1402–1418. doi:
40 10.1016/j.neuroimage.2012.02.084
41
42
43
44
45 15. Nedelska Z, Andel R, Laczó J, et al. Spatial navigation impairment is proportional to right
46 hippocampal volume. *Proc Natl Acad Sci U S A* 2012;109(7):2590–2594. doi:
47 10.1073/pnas.1121588109
48
49
50
51
52 16. Horinek D, Petrovicky P, Hort J, et al. Amygdalar volume and psychiatric symptoms in
53 Alzheimer's disease: an MRI analysis. *Acta Neurol Scand* 2006;113(1):40–45. doi:
54 10.1111/j.1600-0404.2006.00540
55
56
57
58
59
60

- 1
2
3 17. Kerbler GM, Nedelska Z, Fripp J, et al. Basal Forebrain Atrophy Contributes to
4
5 Allocentric Navigation Impairment in Alzheimer's Disease Patients. *Front Aging Neurosci*
6
7 2015;7:185. doi: 10.3389/fnagi.2015.00185
8
9
- 10 18. Nelson HE. The National Adult Reading Test (NART): test manual. Windsor: NFER-
11
12 Nelson 1982.
13
- 14 19. Topinkova E, Jirak R, Kozeny J. Krátká neurokognitivní baterie pro screening demence v
15
16 klinické praxi: sedmiminutový screeningový test. *Neurol. pro Praxi* 2002;6: 323–328.
17
18
- 19 20. Bezdicek O, Stepankova H, Motak L, et al. Czech version of Rey Auditory Verbal
20
21 Learning test: normative data. *Neuropsychol Dev Cogn B Aging Neuropsychol Cogn*
22
23 2014;21(6):693–721. doi: 10.1080/13825585.2013.865699
24
25
- 26 21. Benedict RHB, Schretlen D, Groninger L, et al. Revision of the brief visuospatial memory
27
28 test: Studies of normal performance, reliability, and validity. *Psychological Assessment*
29
30 1996;8(2):145–153. doi: 10.1037/1040-3590.8.2.145
31
32
- 33 22. Meyers JE, Meyers KR. Rey Complex Figure Test and Recognition Trial: Professional
34
35 manual. Odessa, FL: Psychological Assessment Resources 1995.
36
37
- 38 23. Bezdicek O, Lukavsky J, Stepankova H, et al. The Prague Stroop Test: Normative
39
40 standards in older Czech adults and discriminative validity for mild cognitive impairment in
41
42 Parkinson's disease. *J Clin Exp Neuropsychol* 2015;37(8):794–807. doi:
43
44 10.1080/13803395.2015.1057106
45
46
- 47 24. Wechsler D. WAIS-III - Wechslerova inteligenční škála pro dospělé. Praha: Hogrefe-
48
49 Testcentrum 2010.
50
- 51 25. Loonstra AS, Tarlow AR, Sellers AH. COWAT metanorms across age, education, and
52
53 gender. *Appl Neuropsychol* 2001;8(3):161–166. doi: 10.1207/S15324826AN0803_5
54
55
56
57
58
59
60

- 1
2
3 26. Mazancova AF, Nikolai T, Stepankova H, et al. The Reliability of Clock Drawing Test
4 Scoring Systems Modeled on the Normative Data in Healthy Aging and Nonamnesic Mild
5 Cognitive Impairment. *Assessment* 2017;24(7):945–957. doi: 10.1177/1073191116632586
6
7
8
9
10 27. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules.
11
12 *Neurology* 1993;43:2412–2414. doi: 10.1212/WNL.43.11.2412-a
13
14
15 28. Pfeffer RI, Kurosaki TT, Harrah CH, et al. Measurement of functional activities in older
16 adults in the community. *J Gerontol* 1982;37(3):323–329. doi: 10.1093/geronj/37.3.323
17
18
19 29. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety:
20 psychometric properties. *J Consult Clin Psychol* 1988;56(6):893–897. doi: 10.1037/0022-
21
22 006X.56.6.893
23
24
25
26 30. Thomas-Antérion C, Ribas C, Honoré-Masson S, et al. Le questionnaire de plainte
27 mnésique (QPC): un outil de recherche de plainte suspecte d'évoquer une maladie
28 d'Alzheimer. *L'Année Gériatologique* 2003;17(1):56–65.
29
30
31
32
33 31. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual
34 physical activity in epidemiological studies. *Am J Clin Nutr* 1982;36(5):936–42. doi:
35
36 10.1093/ajcn/36.5.936
37
38
39
40 32. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness
41 scale. *Sleep* 1991;14(6):540–545. doi: 10.1093/sleep/14.6.540
42
43
44
45 33. Reguli Z, Svobodová L. Czech version of the diagnosis of fear of falls in seniors - FES-I
46 (Falls Efficacy Scale International). *Studia Sportiva* 2011;5(2):5–12.
47
48
49 34. Hort J, Laczó J, Vyhnalek M, et al. Spatial navigation deficit in amnesic mild cognitive
50 impairment. *Proc Natl Acad Sci U S A* 2007;104(10):4042–4047. doi:
51
52 10.1073/pnas.0611314104
53
54
55
56
57
58
59
60

- 1
2
3 35. Laczó J, Vlcek K, Vyhnalek M, et al. Spatial navigation testing discriminates two types of
4
5 amnesic mild cognitive impairment. *Behav Brain Res* 2009;202(2):252–259. doi:
6
7 10.1016/j.bbr.2009.03.041
8
9
10 36. Laczó J, Andel R, Vyhnalek M, et al. From morris water maze to computer tests in the
11
12 prediction of Alzheimer's disease. *Neurodegener Dis* 2012;10(1–4):153–157. doi:
13
14 10.1159/000333121
15
16
17 37. Varjassyová A, Hořínek D, Andel R, et al. Recognition of Facial Emotional Expression in
18
19 Amnesic Mild Cognitive Impairment. *J Alzheimers Dis* 2013;33(1):273–280. doi:
20
21 10.3233/JAD-2012-120148
22
23
24 38. Keane J, Calder AJ, Hodges JR, et al. Face and emotion processing in frontal variant
25
26 frontotemporal dementia. *Neuropsychologia* 2002;40(6):655–665. doi: 10.1016/S0028-
27
28 3932(01)00156-7
29
30
31 39. Papp KV, Amariglio RE, Dekhytar M, et al. Development of a psychometrically
32
33 equivalent short form of the Face-Name Associative Memory Exam for use along the early
34
35 Alzheimer's disease trajectory. *Clin Neuropsychol* 2014;28(5):771–785. doi:
36
37 10.1080/13854046.2014.911351
38
39
40 40. Buschke H, Mowrey WB, Ramratan WS, et al. Memory Binding Test Distinguishes
41
42 Amnesic Mild Cognitive Impairment and Dementia from Cognitively Normal Elderly. *Arch*
43
44 *Clin Neuropsychol* 2017;32(1):29–39. doi: 10.1093/arclin/acw083
45
46
47 41. Holden HM, Hoebel C, Loftis K, et al. Spatial pattern separation in cognitively normal
48
49 young and older adults. *Hippocampus* 2012;22(9):1826–1832. doi: 10.1002/hipo.22017
50
51
52 42. Sheardova K, Laczó J, Vyhnalek M, et al. Famous landmark identification in amnesic
53
54 mild cognitive impairment and Alzheimer's disease. *PLoS One* 2014;9(8). doi:
55
56 10.1371/journal.pone.0105623
57
58
59
60

- 1
2
3 43. Vlcek K, Laczó J, Vajnerová O, et al. Spatial navigation and episodic-memory tests in
4 screening of dementia. *Psychiatrie* 2006;10:35–38.
5
6
7 44. Marková H, Laczó J, Andel R, et al. Perspective taking abilities in amnesic mild
8 cognitive impairment and Alzheimer's disease. *Behav Brain Res* 2015;281:229–38. doi:
9
10 10.1016/j.bbr.2014.12.033
11
12
13 45. Gomez R, Fisher JW. Domains of spiritual well-being and development and validation of
14 the Spiritual Well-Being Questionnaire. *Pers Individ Dif* 2003;35(8):1975–1991. doi:
15
16 10.1016/S0191-8869(03)00045-X
17
18
19 46. OPD Working Group. Operationalized Psychodynamic Diagnostics: Foundations and
20 Manual. Hogrefe & Huber Pub 2001.
21
22
23 47. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment
24 due to Alzheimer's disease: recommendations from the National Institute on Aging-
25 Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 51. Mokrisova I, Laczko J, Andel R, et al. Real-space path integration is impaired in
4
5 Alzheimer's disease and mild cognitive impairment. *Behav Brain Res* 2016;307:150–158. doi:
6
7 10.1016/j.bbr.2016.03.052
8
9
10 52. Laczko J, Andel R, Nedelska Z, et al. Exploring the contribution of spatial navigation to
11
12 cognitive functioning in older adults. *Neurobiol Aging* 2017;51:67–70. doi:
13
14 10.1016/j.neurobiolaging.2016.12.003
15
16
17 53. Hort J, Andel R, Mokrisova I, et al. Effect of Donepezil in Alzheimer Disease Can Be
18
19 Measured by a Computerized Human Analog of the Morris Water Maze. *Neurodegener Dis*
20
21 2014;13(2–3):192–196. doi: 10.1159/000355517
22
23
24 54. Laczko J, Andel R, Vyhnalek M, et al. APOE and spatial navigation in amnesic MCI:
25
26 results from a computer-based test. *Neuropsychology* 2014;28(5):676–684. doi:
27
28 10.1037/neu0000072
29
30
31 55. Laczko J, Andel R, Vyhnalek M, et al. The effect of TOMM40 on spatial navigation in
32
33 amnesic mild cognitive impairment. *Neurobiol Aging* 2015;36(6):2024–2033. doi:
34
35 10.1016/j.neurobiolaging.2015.03.004
36
37
38 56. Parizkova M, Andel R, Lerch O, et al. Homocysteine and Real-Space Navigation
39
40 Performance among Non-Demented Older Adults. *J Alzheimers Dis* 2017;55(3):951–964. doi:
41
42 10.3233/JAD-160667
43
44
45 57. Vyhnalek M, Nikolai T, Andel R, et al. Neuropsychological Correlates of Hippocampal
46
47 Atrophy in Memory Testing in Nondemented Older Adults. *J Alzheimers Dis* 2014;42(3):81–
48
49 90. doi: 10.3233/JAD-132642
50
51
52 58. Sheardova K, Nedelska Z, Sumec R, et al. The effect of spiritual well-being
53
54 (transcendental and non-transcendental domain) on regional brain atrophy in non-demented
55
56 subjects with memory complaints: 3-year follow up data from the czech brain aging study
57
58
59
60

1
2
3 [abstract]. *Alzheimers Dement* 2018; 14(Suppl 7):P587–P588. doi:

4
5 <https://doi.org/10.1016/j.jalz.2018.06.654>

6
7
8 59. Chanti-Ketterl M, Andel R, Lerch O, et al. Cholesterol and cognitive performance among
9 community volunteers from the Czech Republic. *Int Psychogeriatr* 2015;27(12):2087–2095.

10
11
12 doi: 10.1017/S1041610215000320

13
14 60. Pappas C, Small BJ, Andel R, et al. Blood Glucose Levels May Exacerbate Executive
15 Function Deficits in Older Adults with Cognitive Impairment. *J Alzheimers Dis* 2019;
16
17 67(1):81-89. doi: 10.3233/JAD-180693

18
19
20 61. Sumec R, Sheardova K, Marciniak R, et al. Meditation's impact on cognitive functions in
21 mild cognitive impairment: A pilot study. *Biomed Pap Med Fac Univ Palacky Olomouc*
22
23
24
25
26
27
28 *Czech Repub* 2017;161(1):54–56

29
30 62. Tillmann T, Pikhart H, Peasey A, et al. Psychosocial and socioeconomic determinants of
31 cardiovascular mortality in Eastern Europe: A multicentre prospective cohort study. *PLoS*
32
33
34
35 *Med* 2017;14(12):e1002459. doi: 10.1371/journal.pmed.1002459


36
37 63. Brayne C, Davis D. Making Alzheimer's and dementia research fit for populations. *Lancet*
38
39
40 2012;380(9851):1441–1443. doi: 10.1016/S0140-6736(12)61803-0.

41
42 64. Sachdev PS, Lipnicki DM, Kochan NA, et al. The Prevalence of Mild Cognitive
43 Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration.
44
45
46
47
48
49
50 *PLoS One* 2015;10(11):e0142388. doi: 10.1371/journal.pone.0142388

51 **Figure legends:**

52
53 Figure 1 The frequency of vascular risk factors in CBAS cohort

Vascular risk factors frequency in CBAS cohort (%)



STROBE (Strengthening The Reporting of OBServational Studies in Epidemiology) Checklist

A checklist of items that should be included in reports of observational studies. You must report the page number in your manuscript where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript accordingly before submitting or note N/A.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

Section and Item	Item No.	Recommendation	Reported on Page No.
Title and Abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	
Introduction			
Background/Rationale	2	Explain the scientific background and rationale for the investigation being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	
Methods			
Study Design	4	Present key elements of study design early in the paper	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	

Section and Item	Item No.	Recommendation	Reported on Page No.
Data Sources/ Measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	
Study Size	10	Explain how the study size was arrived at	
Quantitative Variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical Methods	12	(a) Describe all statistical methods, including those used to control for confounding	
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive Data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome Data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	

Section and Item	Item No.	Recommendation	Reported on Page No.
Main Results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other Analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key Results	18	Summarise key results with reference to study objectives	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	
Other Information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this checklist as part of the main manuscript document. It must be uploaded as a separate file.

BMJ Open

Cohort Profile: "The Czech Brain Aging Study (CBAS) – prospective multicenter cohort study on risk and protective factors for dementia in the Czech Republic"

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030379.R2
Article Type:	Cohort profile
Date Submitted by the Author:	04-Oct-2019
Complete List of Authors:	Sheardova, Katerina; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice u svate Anny v Brne, NEUROLOGY DEPARTMENT Vyhnaek, Martin; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Nedelska, Zuzana; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Laczo, Jan; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Andel, Ross; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; University of South Florida, School of Aging Studies Marciniak, Rafal; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center Cerman, Jiri; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Lerch, Ondrej; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Hort, Jakub; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Mental health, Public health, Neurology
Keywords:	Dementia < NEUROLOGY, EPIDEMIOLOGY, MENTAL HEALTH

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3 **Cohort Profile: “The Czech Brain Aging Study (CBAS) – prospective multicenter cohort**
4 **study on risk and protective factors for dementia in the Czech Republic”**
5
6
7

8
9 Katerina Sheardova^{1,2} *, Martin Vyhnalek^{1,3}, Zuzana Nedelska^{1,3}, Jan Laco^{1,3}, Ross Andel^{1,4},
10
11 Rafal Marciniak^{1,2}, Jiri Cerman^{1,3}, Ondrej Lerch^{1,3}, Jakub Hort^{1,3}
12
13

14
15 ¹International Clinical Research Center, St. Anne’s University Hospital, Brno, Czech
16
17 Republic
18

19 ²Department of Neurology, St. Anne’s University Hospital, Brno, Czech Republic
20

21 ³Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and
22
23 Motol University Hospital, Prague, Czech Republic
24

25
26 ⁴School of Aging Studies, University of South Florida, Tampa, USA
27
28
29
30
31
32

33 Corresponding author:
34

35 Katerina Sheardova, MD,
36

37 International Clinical Research Center
38

39 Fakultní nemocnice u Svaté Anny v Brně
40

41 Pekarska 53, 656 91 Brno, Czech Republic
42

43 e-mail.: ksheardova@gmail.com
44

45
46 Phone: +420603198029
47
48
49
50
51

52
53 Word count 3 963
54
55
56
57
58
59
60

ABSTRACT

Purpose: Identification of demographic, physical/physiological, lifestyle, and genetic factors contributing to the onset of dementia specifically, Alzheimer disease (AD), and implementation of novel methods for early diagnosis are important to alleviate prevalence of dementia globally. The Czech Brain Aging Study (CBAS) is the first large, prospective study to address these issues in Central/Eastern Europe by enrolling non-demented adults aged 55+, collecting a variety of personal and biological measures, and tracking cognitive function over time.

Participants: The CBAS recruitment was initiated in 2011 from memory clinics at Brno and Prague University Hospitals, and by end of 2018, the study included 1228 participants. Annual follow-ups include collection of socioeconomic, lifestyle and personal history information, neurology, neuropsychology, laboratory, vital sign and brain MRI data. In a subset, biomarker assessment (CSF, amyloid PET) and spatial navigation are performed. Participants are 69.7 ± 8.1 years old, have 14.6 ± 3.3 years of education at baseline, and 59% are women. By the end of 2018, 31% finished 3 and more years of follow-up, 9% converted to dementia. APOE status is available from 95% of participants. Biological sample bank linked to CBAS database contains CSF, serum and DNA.

Findings to date: Overall, the findings, mainly from cross-sectional analyses, indicate that spatial navigation is a promising marker of early AD and that it can be distinguished from other cognitive functions. Specificity of several standard memory tests for early AD pathology was assessed with implications for clinical practice. The relationship of various lifestyle factors to cognition and brain atrophy was reported.

Future plans: Recruitment is on-going with secured funding. Longitudinal data analyses are currently being conducted. Proposals for collaboration on specific data from the database or

1
2
3 biospecimen, as well as collaborations with similar cohort studies to increase sample size, are
4
5 welcome. Study details are available at www.cbac.cz.
6
7
8
9
10

11
12 Key words: Dementia, epidemiology, mental health
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STRENGTHS AND LIMITATIONS OF THE STUDY:

- CBAS is a prospective longitudinal study of cognitive and brain aging that combines prospective data on lifestyle, genetic, neuropsychological, social, physical and biological factors with neuropsychological and imaging data in the context of AD biomarkers.
- Although biomarkers are available for most cognitively impaired participants, only a subsample of participants with subjective memory complaints and cognitively normal controls has biomarkers available.
- Participants come from university hospital-based memory clinics from two major Czech cities—Brno and Prague—which limits generalizability, although universal health care coverage promotes university hospital visits by a more diverse patient population with respect to urban/rural living and socioeconomic status.
- CBAS has the potential to serve as a crucial, comprehensive source of information about markers of cognitive decline and impairment and can represent a model for studying risk/protective factors for AD in other Central and Eastern European countries.

INTRODUCTION

A gradual increase in the prevalence of dementia has been one of the trends accompanying the growth in life expectancy seen across the globe over the past few decades. Dementia affects 1% of those 60 to 65 years of age and about 45% of those aged 90–95 years,[1, 2] although there is also evidence suggesting that the prevalence as well as incidence of dementia has decreased in the last decade.[3, 4]. This downwards trend may be the result of treatment of hypertension and diabetes as well as greater attention to lifestyle factors stemming from the

1
2
3 increasing awareness of its impact on cognitive and overall health among the general public.
4
5 Still dementia remains a major public health issue. Currently, the course of dementia can only
6
7 be modified by symptomatic therapies and no causal treatment for its most common form,
8
9 Alzheimer disease (AD), or for other neurodegenerative disorders is available. A crucial step
10
11 in an effective management of dementia including AD is to better understand the underlying
12
13 neuropathological mechanisms and the differences in ethnic and lifestyle risk factors. An
14
15 important effort in this context involves the identification of the extent to which demographic,
16
17 physical/physiological, lifestyle, and genetic factors contribute to the onset of dementia and
18
19 AD specifically.
20
21
22

23
24 A parallel effort to searching for risk factors includes early identification of cognitive
25
26 impairment. To further alleviate dementia incidence on the global level, novel diagnostic
27
28 methods need to be implemented to define the risk factors for conversion from preclinical to
29
30 early symptomatic (prodromal) stage and to dementia. Presumably, an early, accurate
31
32 diagnosis is a crucial, yet still elusive, step in the pursuit of effective treatments for dementia.
33
34

35
36 The Czech Brain Aging Study (CBAS) is the first large, prospective study to address these
37
38 issues in Eastern Europe. CBAS was designed to study potential early biomarkers and
39
40 risk/protective factors of cognitive decline and dementia by enrolling a large number of older
41
42 adults, collecting a variety of information about personal and family history, past and current
43
44 lifestyle, genetic, physical and biological measures, and tracking cognitive function and status
45
46 and brain MRI of the participants over time. Czech Republic (CR) has approximately 150,000
47
48 patients with dementia among its roughly 10.6 million inhabitants. CR, like other Eastern
49
50 European countries, is unique in a number of ways including a relatively high prevalence of
51
52 cardiovascular issues. However, since the 1980s, the frequency of common vascular risk
53
54 factors is continuously decreasing, and the mortality associated with vascular risk factors in
55
56 CR and neighboring countries such as Poland has been significantly lower compared to other
57
58
59
60

1
2
3 Eastern European countries, such as Russia. Although the cause of this remains mainly
4 unexplained improved prevention and education are especially suggested.[5, 6]

7 Another unique feature of health care delivery in the CR is a care delivery system that favors
8 memory clinic visits from a wide spectrum of the patient population. In turn, prodromal stages
9 of the disease are mostly handled by neurologists, whereas post-diagnostic patients are more
10 often seen by geriatricians and psychiatrists.[7] Neurologists generally tend to employ more
11 sophisticated diagnostic tools for detecting early stages of cognitive deficit and assessment of
12 its etiology than psychiatrists/geriatricians.

13 Building on this model, CBAS was established using recruitment from two memory clinics at
14 two independent neurology departments based at university hospitals in Prague and Brno,
15 respectively. Data collection started 2005 in Prague and the extension to a multicenter design
16 was possible in 2011 thanks to the European Union Regional Development Fund. The main
17 aim of both memory clinics is to diagnose and treat neurological disorders that lead to
18 cognitive disorders and dementia. Both centers are harmonized in terms of
19 neuropsychological battery, multimodality magnetic resonance imaging (MRI), PET imaging,
20 genetic testing, blood tests and cerebrospinal fluid (CSF) analysis, the set of questionnaires,
21 and a participant database system.

22 Although CBAS lacks the advantages of a population-based study, it uses the only currently
23 feasible design for this type of study in the CR. In addition, it provides access to a relatively
24 large number of clinical patients. A population-based study would need to include much
25 larger numbers to recruit the same number of at-risk patients, which would deem the study
26 unfeasible under the current funding mechanisms.

27 The overarching objectives of CBAS are to help understand lifestyle, genetic, and biological
28 factors influencing variability in the onset of cognitive impairment including AD and finding
29 novel ways of early AD diagnosis. The specific aims are: 1. Exploring epidemiological risk
30

1
2
3 factors for cognitive decline and dementia in the CR; 2. Evaluation of spatial navigation and
4 other experimental neuropsychological tests as early markers of AD pathology; 3. Defining
5 structural, metabolic and functional biomarkers of neurodegenerative diseases in older adults;
6 and 4. Exploring non-pharmacological interventions in prevention of cognitive decline.
7
8
9
10
11

12 **COHORT DESCRIPTION**

14 **Settings**

15
16 CBAS is a prospective longitudinal memory clinic based multi-center study recruiting non-
17 demented adults 55+ years of age. Both CBAS centers work as a low threshold facility; hence
18 the participants are mostly volunteers who come as a self-referral with memory complaints
19 expressed by themselves or the family or who were referred by general practitioners, local
20 specialists or the Czech Alzheimer Society to one of the memory clinics.
21
22
23
24
25
26
27

28 **Eligibility Criteria**

29
30 All participants entering the two memory clinics undergo neurological examination, brain CT
31 or MRI, and cognitive assessment, excluding subjects with dementia. All non-demented
32 subjects aged 55+ years who are able to undergo MRI examination and are eligible (see
33 exclusion criteria below) are initially offered to participate in CBAS. About 95% of these
34 subjects agreed to enter the study. The additional exclusion criteria are severe depression
35 (participants with a recent bout of mild depression are included), a diagnosis of neurological
36 or other psychiatric disorder, a systemic condition potentially causing cognitive impairment,
37 or a recent history of stroke. Participants referred for newly developed cognitive complaints in
38 whom no objective cognitive deficit is found are categorized as subjective cognitive decline
39 (SCD). Participants with objective cognitive decline are classified as mild cognitive
40 impairment (MCI) based on 2011 NIA-AA guidelines by Albert and colleagues.[8]
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

clinical interview and with no objective cognitive deficit, are recruited from adults taking continuing education classes under the University of the Third Age at Charles University and from relatives of employees or of study participants.

Written informed consent was obtained from each participant prior to entering the study. The Ethics Committees of Motol University Hospital and St. Anne's University Hospital approved the study.

Cohort Characteristics

Between January 2011 and December 2018, 1228 subjects who fulfilled the CBAS criteria agreed to enter the study. Brno has contributed 496 and Prague 732 participants so far, with enrollment accelerated at both sites more recently. The basic characteristics of this cohort are presented in table 1, the frequency of vascular risk factors is in figure 1. The frequencies of these vascular risk factors in CBAS are similar to national reports and studies, almost solely conducted by cardiologists and internal medicine specialists in CR,[5] although the proportion of smokers is lower in CBAS compared to national average reported in 2004.

Table 1. Basic characteristics of the CBAS cohort at baseline

	Total			SCD			MCI			NC		
	mean (SD) or ratio	median or %	Inter quartile range	mean (SD) or ratio	median or %	Inter quartile range	mean (SD) or ratio	median or %	Inter quartile range	mean (SD) or ratio	median or %	Inter quartile range
No. of participants	1228			428			732			68		
Gender (M/F)	502/726	40.9%M		146/282	34.1%M		329/403	44.9%M		27/41	39.7%M	
Age/years	69.7 (8.0)	70	64-75	67.1 (7.9)	66	61-72	71.2 (7.9)	72	66-77	68.9 (7.1)	69	64-73
Education/years	14.6 (3.3)	14	12-17	15.2 (3.0)	15	13-18	14.3 (3.4)	13	12-17	16.1 (3.4)	16	13-17
Depression (GDS)	3.86 (3.1)	3	2-5	3.9 (3.0)	3	2-5	4.0 (3.2)	3	2-6	1.6 (1.3)	1	0-1

Notes: SD = standard deviation; GDS = Geriatric Depression Scale[9]

Apolipoprotein E4 (APOE; and its $\epsilon 4$ allele, specifically) is the strongest genetic risk factor for late onset AD, and is associated with impairments in cerebral metabolism and cerebrovascular function. About 30% of the participants carry at least one APOE $\epsilon 4$ allele.

The dataset includes 15.2% of APOE $\epsilon 4$ allele heterozygotes and 5.4% homozygotes in MCI

1
2
3 subjects, 7.2% heterozygotes and 2.1% homozygotes in SCD subjects and only 1.2%
4
5 heterozygotes in NC subjects. About 25% of the subjects are living alone and the rest are
6
7 living with a spouse, friend, or a family member. All participants are community dwelling.
8
9
10 The age of the cohort reflects the age distribution of older adults in the CR, with 12% of the
11
12 subjects 80+ years of age, and 4% 85+ years of age at baseline. There are 3.3 million people
13
14 aged 55+ living in the CR, 12% of whom are 80+ and 6% are 85+ according to the 2018
15
16 Czech Census data. Education of our cohort is slightly higher than the average education level
17
18 of 55+ population in the CR; 7.3% of the CBAS participants finished basic education (vs.
19
20 26% in the CR), 68% finished secondary (high school) education (vs. 62% in the CR) and
21
22 48% achieved college/university degree (vs. 9% in the CR). Efforts are under way to recruit a
23
24 more diverse cohort.
25
26

27
28 Aside from the CBAS cohort defined above, the “CBAS Plus” database is also available,
29
30 containing baseline data from 155 Brno and 283 Prague subjects who did not meet the CBAS
31
32 inclusion criteria due to mild dementia of various neurodegenerative origin, depression,
33
34 history of stroke etc. and who signed informed consent. Dementia etiology (AD dementia,
35
36 frontotemporal lobar degeneration, Parkinsonian syndromes, vascular disorders etc.) is
37
38 diagnosed according to established guidelines.[10] The CBAS Plus cohort reflects a real
39
40 memory clinic patient profile and therefore can provide clinically relevant and important data
41
42 about a wide spectrum of neurological brain diseases leading to dementia and the role of
43
44 vascular risk factors and psychiatric co-morbidity.
45
46
47
48

49 **Methods**

50
51 At each visit, all study participants undergo a standard set of procedures. Neurological and
52
53 comprehensive neuropsychology examination including Uniform Data Set (UDS) battery is
54
55 administered;[11, 12] laboratory and vital functions assessments are also performed. Socio-
56
57 demographic, personal, pharmacological and family history data are collected. Participants
58
59
60

and their informants complete multiple questionnaires about cognitive complaints and lifestyle factors. 1.5T or 3T MRI scans are performed every 24 months or earlier when a participant converts to dementia or progresses towards cognitive impairment at an unusual rate. Volumetric MRI is analyzed in all patients to obtain measures of regional cortical thickness and subcortical volumes cross-sectionally and longitudinally using Freesurfer image analysis suite (v5.3; <http://surfer.nmr.mgh.harvard.edu/>). The details of Freesurfer image processing have been published elsewhere,[13-15] including previous studies by our group.[16, 17] A subset of MRI volumes has been previously measured using manual tracing and a subset of participants' MRI volumes is used to measure the atrophy of the cholinergic basal forebrain nuclei.[18] Genotyping is carried out at baseline. In a subset, CSF and/or amyloid PET is performed and additional data are collected from experimental neuropsychology, spatial navigation and personality trait assessment. The detailed procedures including their timelines are presented in table 2.

Table 2. The CBAS Procedures

Frequency	Procedure	Specification
Annually	Clinical exam	Standard complex neurology examination
Annually	Standard neuropsychology	<p>Uniform Data Set[11, 12]: Mini-Mental State Examination, Digit Span Forward and Backward, Digit Symbol, Trail Making Test A and B, Animal list generation, Vegetable list generation, Boston Naming Test (30 odd items), Logical Memory, Story A</p> <p>Premorbid ability estimation: National Adult Reading Test[19]</p> <p>Memory assessment: Enhanced cued recall test,[20] Rey Auditory Verbal Learning Test,[21] Brief Visuospatial Memory Test–Revised,[22] Rey-Osterrieth Complex Figure Test – (ROCFT) recall[23]</p> <p>Executive functions: Prague Stroop test,[24] Similarities (WAIS-R)[25], Controlled Oral Word Association Test[26]</p> <p>Visuoconstruction: Clock Test,[27] ROCFT copy[23]</p> <p>Functional scales: Clinical Dementia Rating scale,[28] Functional assessment questionnaire[29]</p> <p>Symptoms of anxiety and depression: Geriatric Depression Scale (15 items version),[9] Beck Anxiety Inventory[30]</p>

1	Annually	Laboratory	Fasting glucose, lipid profile, homocysteine, vitamin B12, thyroid hormones, folic acid, renal and liver function, C-reactive protein, glycosylated hemoglobin
2	Annually	Vital functions	blood pressure, pulse frequency, waist/hips ratio, BMI
3	Annually	Socio- economic data	Marital status, Type of living, Current occupation
4	Annually	Questionnaires	Subjective cognitive complaints (QPC),[31] physical/mental activity at midlife and currently, Becke's Habitual Physical Activity[32], Epworth Sleepiness Scale,[33] Falls Self-Efficacy Scale – International[34]
5	Biannually	MRI	1.5T protocol: plane localizer; standard clinical T2; T1 3-dimensional isometric magnetization-prepared rapid gradient echo(MPRAGE) with isometric voxel; fluid-attenuated inversion recovery(FLAIR); T2*; echoplanar imaging for diffusion tensor imaging with 32directions.3T protocol: plane localizer; standard clinical T1 and T2; T1 3-dimensional isometric magnetization-prepared rapid gradient echo (MPRAGE) with isometric voxel; echoplanar imaging for diffusion tensor imaging with 64 directions; fluid-attenuated inversion recovery (FLAIR); T2 fast spin echo;T2*; resting state functional MRI. Switch to 3T MRI since 2015 in Brno, since 2019 in Prague
6	At baseline	Demography	Age, education, occupation, laterality
7	At baseline all	Genotyping	APOE
8	Optional		TOMM40, BDNF, CD36, BuChE, KIBRA, TREM2, PSEN 1, PSEN 2, APP, TARDBP, MAPT, GRN, C9orf72
9	Subset at both centres	CSF	Amyloid β -42, total, tau, p-tau, oligoclonal bands, CSF biochemistry,
10	Subset at both centres	Amyloid PET	PET/MRI or PET/CT (visual assessment), flutemetamol, dual phase ("perfusion") PET;
11	Prague cohort all	Spatial navigation[35, 36, 37]	hidden goal task, simple navigation task, path integration task, Y-maze assessment, intersections task, sea hero quest, spatial tasks in virtual reality/augmented virtual reality
12	Prague cohort optional	Experimental neuropsychology	Facial emotion recognition,[38, 39] Famous faces identification,[39] FNAME 12 items version,[40] Memory binding test,[41] spatial pattern separation task[42] In house developed tests: Famous landmarks identification,[43] episodic-like memory test,[44] Arena Perspective Taking Task[45]
13	Brno cohort All at baseline	Specific questionnaires	Spiritual well-being questionnaire (SHALOM),[46] Operationalized Psychodynamic Diagnostics OPD-2 (OPD working group),[47] early life trauma assessment

The CBAS is complemented by a biological sample bank linked to data from the CBAS and “CBAS Plus” cohorts. The CSF collection and storage are carried out after signing an informed consent in accordance with the ethical guidelines in the CR and good clinical practice, and according to the widely recognized consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.[48] Eighteen aliquots of 0.2ml CSF and 5-9 aliquots of serum are stored for each participant. All samples are stored at -80C. Commercial ELISA kits (Innogenetics®) are used for dementia biomarker analyses (Aβ1-42, protein tau, and phospho-tau) and cut off values derived from validation study are used.[49] The characteristics of the biobank as of December 2018 are listed in table 3.

Table 3. Biobank characteristics

	Aliquots per patient stored at -80C	No. of participants
CSF	18x0.2ml	75 in Brno/350 in Prague
Serum	5-9x0.5ml	145 in Brno/350 in Prague
DNA	concentration >100 ng/μl	95% of all participants

Follow-up

Participants are examined annually; they are invited for a follow-up via a letter mailed to their permanent address. Subsets of SCDs and NC who are cognitively stable for the first 3 visits are followed every other year. At each follow-up visit, all participants undergo a standard set of procedures described in the Methods section; see table 2 for additional details. Standard criteria-based consensus diagnosis is performed based on each visit. MCI and dementia etiology is based on biomarkers.[8, 10]

Progression from NC/SCD to MCI or to dementia, and from MCI to dementia is the main outcome, along with longitudinal quantitative measures of cognitive performance, which are used for evaluation of early markers of AD and risk factors for progression. Participants are censored when they progress to dementia as ascertained by panel consensus conference or if they can no longer undergo an MRI examination. Between entering the study and the end of

1
2
3 2018, 31% of the total of 1228 participants already completed at least 3 full yearly evaluations
4
5 (baseline + 2 follow up visits) with at least 2 brain MRI sessions. Additionally, 9% of all
6
7 participants converted to dementia at some timepoint within their follow-up and were no
8
9 longer followed, and 16% of the participants were lost to follow-up for various reasons (loss
10
11 of interest, newly acquired MRI intolerance, worsening health condition, change of residence
12
13 address not allowing invitation for follow up, etc.). From all participants recruited by the end
14
15 of 2018, 931 (75%) continue in the study. The recruitment is ongoing with secured funding.
16
17 We have just reached a sufficient number of longitudinally followed participants to begin with
18
19 longitudinal data analyses which will contribute significantly to the fulfillment of most of the
20
21 study aims.
22
23
24
25

26 **Patient and public involvement**

27
28 Patient involvement was crucial in questionnaire implementation. Initial versions of
29
30 questionnaires were consulted with a pilot group of patients and their caregivers. Based on
31
32 their feedback, we excluded McNair's questionnaire of activities of daily living. The
33
34 adaptation of Mild Behaviour impairment checklist was graphically reworked after being
35
36 consulted with our participants increasing the rate of successful completion considerably. In
37
38 the tests developed by our team, such as the Famous Landmark Identification Test[43] or the
39
40 Subjective Spatial Memory Complaints Questionnaire,[50] we consulted our participants
41
42 during the entire development process including the selection of relevant items. Some of the
43
44 items were generated from qualitative research which always preceded the development of
45
46 new questionnaires. These procedures ensured high participation and validity.
47
48
49

50
51 Wider public engagement is ensured by public lectures regularly performed by the CBAS
52
53 team members, which inform the public about the study, its goals and procedures. Partial
54
55 results concerning lifestyle are discussed. The information about the study and the
56
57 possibilities to join are communicated to the public via various channels including the
58
59
60

1
2
3 Concept Alzheimer Café, CBAS webpage, etc. We also closely cooperate with Czech
4
5 Alzheimer Association (CAA) connecting dementia specialists with patients and their
6
7 caregivers. Many CAA members and participants of the study help disseminate information
8
9 about the study which facilitates recruitment.
10

11 **FINDINGS TO DATE**

12
13
14 Data collected from the CBAS and CBAS plus cohorts have spurred more than 60
15
16 publications so far mainly from cross-sectional analyses, primarily in impacted neurology and
17
18 neuroscience journals (the complete list is available at www.cbass.cz). We highlight the most
19
20 significant ones here in the context of the aims of the study.
21
22

23 **Early markers of AD**

24 Spatial navigation

25
26 Spatial navigation testing is part of the baseline CBAS protocol[35, 36] (for details see table
27
28 2). Outcomes of this comprehensive examination have been compared with results of
29
30 structural brain MRI and genetic and laboratory assessment. Our cross-sectional studies using
31
32 clinically and biomarker-defined individuals with AD[51] have shown that spatial navigation
33
34 is a distinct cognitive function and a promising cognitive marker of early stages of AD, the
35
36 assessment of which may add important information to a comprehensive neuropsychological
37
38 profile of individuals in the CBAS study[52, 53] and may be useful for early and differential
39
40 diagnosis of AD, or for evaluating the effect of therapies.[37, 54] Longitudinal study will aim
41
42 to provide evidence for this notion. It should be noted that other co-pathologies may
43
44 negatively impact on spatial navigation performance in individuals with AD.[55, 56]
45
46
47 We have found that impairment of spatial navigation is associated with structural changes of
48
49 the right hippocampus, entorhinal cortex, posterior parietal lobe and basal forebrain, i.e. the
50
51 structures that are impaired very early in AD[16, 18, 52] and that it can be influenced by genetic
52
53 background[57, 58] and cardiovascular risk factors.[59]
54
55
56
57
58
59
60

Experimental neuropsychology

We have shown that our “in-house” developed Famous Landmarks Identification Test, created with the help from our participants, could be useful in recognizing early stages of AD.[43] We have also tested the specificity of several standard memory tests for estimating hippocampal atrophy in the CBAS participants which could have immediate implications for clinical practice.[60]

Lifestyle factors and AD

We have recently completed the first longitudinal MRI analysis from CBAS[61] showing that the level of spiritual well-being can influence the atrophy rates in regions affected by AD pathology, as well as those associated with attention and with behavioral symptoms. The manuscript is being prepared for publication. Previous studies have included examinations of cholesterol[62] and blood glucose[63] in relation to cognitive outcomes.

Non-pharmacological interventions

We have completed an intervention study with mindfulness-based stress reduction (MBSR) therapy and cognitive training in members of CBAS with MCI. We have shown that MBSR is a suitable intervention for subjects with mild cognitive decline[64] and findings regarding its effect on cognition, immunology profile and depression suggest that MBSR could be effective in secondary prevention. The manuscript is submitted for publication.

STRENGTHS AND LIMITATIONS

CBAS represents a unique effort to study cognitive and brain ageing in Central and Eastern Europe. It is a prospective study of a relatively culturally and genetically homogenous Czech population based mainly on recruitment of volunteers who come to a memory clinic in one of the two largest cities in the country - Prague and Brno. The study includes a large biological sample bank (sera, CSF, DNA) that can enhance diagnostic accuracy and improve predictive validity of analyses with other AD risk factors, such as lifestyle factors and vascular risk

1
2
3 factors. Despite several studies on vascular risk factors, the reasons for the high frequency of
4
5 vascular problems in Eastern Europe, as well as the association between vascular factors and
6
7 cognitive performance,[65] remain poorly understood. We believe that data from our study
8
9 can contribute important information on this topic.
10

11
12 The study also has limitations. While having two sites involved in participant recruitment is
13
14 an advantage, it cannot compete with a population-based recruitment. Although it is also of
15
16 note that due to the nature of health care delivery in the CR, attendance at the two memory
17
18 clinics is far from restricted to the close geographical proximity. Rather, older adults of all
19
20 ages and backgrounds visit the clinics from a variety of geographical areas. Therefore, coding
21
22 of demographics and participant residence (urban vs rural or by region) can enrich analyses
23
24 and help increase interpretability of any findings, and potentially ameliorate this limitation to
25
26 at least some extent. Given the recruitment from university hospital-based clinics, one may
27
28 assume that the sample could attract relatively young patients.[66] However, although the
29
30 average age for patients with MCI is substantially lower than the UK-based Cognitive
31
32 Function & Ageing Studies, it is roughly similar to studies from Italy, Spain, Australia, and
33
34 studies conducted in Asia.[67] Still, results of longitudinal analyses are likely to be affected
35
36 by selective attrition. Additionally, the current sample is relatively highly educated and efforts
37
38 are under way to recruit participants with more diverse educational attainment. However,
39
40 there are also other advantages to basing recruitment on memory clinics, such as the access to
41
42 much higher rates of at-risk patients than is typical for a population-based study, making the
43
44 recruitment approach crucial in terms of study feasibility under the current CBAS funding
45
46 structure.
47
48
49
50
51
52

53
54 Although brain imaging is available for most participants, biomarkers are available only for a
55
56 subsample. Efforts are under way to increase biomarker data availability. Detailed
57
58 information is missing on subjects lost to follow-up. Despite these limitations, to the best of
59
60

our knowledge, CBAS remains the largest coordinated effort to collect longitudinal data in the context of cognitive and brain aging in the Czech Republic and in Eastern Europe in general. CBAS is also unique in its richness of prospective data on lifestyle, genetic, neuropsychological, social, physical and biological factors as predictors of cognitive decline in the context of AD biomarkers. Until a population-based study with the same aim can be carried out within Eastern Europe, the CBAS may serve as the only source of information about a wide variety of risk factors for cognitive impairment in this geographical region. In conclusion, CBAS has the potential to serve as a crucial, comprehensive source of information about markers of cognitive decline and impairment and can represent a model for studying risk/protective factors for AD in other Central and Eastern European countries.

Acknowledgement:

All of the CBAS participants and their relatives are appreciated for their involvement in the project and their dedication.

We would like to thank the heads of Neurology departments Prof. Petr Marusic from Motol University Hospital Prague and Prof. Milan Brazdil from St. Anne's University Hospital Brno for their support. Big appreciation to the supporting CBAS team: neurologists and psychologists, for thorough data collection, study nurses and coordinators for an excellent management of participants and procedures and also to external collaborators: Jitka Hanzalova Motol University Hospital, Prague, for laboratory assessment, Vaclav Matoska from Homolka Hospital, Prague and T. Freiburger from Cardiovascular and Transplant surgery Center Brno for covering the DNA biobank, T. Machulka and S. Belaskova from ICRC Brno for database and statistic support. We would also like to thank the teams from MRI and PET facilities from University Hospitals in Brno and Prague.

FOOTNOTES:

Patient consent for publication: Not required

1
2
3 **Contributors:** KS, JH, MV, JL and ZN conceived the hypothesis and study design, KS, MV,
4 JL, RM, JC, JH collected the data, OL, ZN, RA provided the data analyses, RA is responsible
5 for statistical analyses. All authors had input on interpretation and reporting of study findings.
6
7
8
9
10 KS wrote the first draft; all authors reviewed and edited the final version. All authors provided
11 approval for the published version of this manuscript.
12

13
14 **Funding:** During 2011-2015, CBAS was supported by the project FNUSA-ICRC [grant
15 number CZ.1.05/1.1.00/02.0123] from the European Regional Development Fund. Between
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2016-2020, it is supported by National Program of Sustainability II (Ministry of Education,
Youth and Sports of the Czech Republic) [grant number LQ1605]. The following grants
contributed to specific subprojects based on CBAS: Ministry of Health Internal Grant Agency
[grant number NT 11225-4/2010], Czech Health Research Council [grant numbers 16-
27611A, NV18-04-00455], Motol University Hospital, Prague, Czech Republic [grant number
CZ – DRO 00064203], Institutional Support of Laboratory Research [grant number 2/2012
(699002)], Institutional Support of Excellence 2nd Medical Faculty Charles University [grant
number 699012], Grant Agency of the Czech Republic [grant numbers 309/05/0693,
309/09/1053] and Grant Agency of the Charles University [grant numbers 91007, 74308,
98509, 624012, 546113, 1108214, 135215, 654217, 308216, 546317 and 693018].

42 **Competing interests:** None declared.

44 **Provenance and peer review:** Not commissioned; externally peer reviewed.

46
47
48
49
50
Ethics approval: The Ethics Committee of Motol University Hospital and St. Anne's
University Hospital approved the study.

51
52
53
54
55
56
57
58
59
60
Collaboration: Proposals for collaboration on specific data from the database or biospecimen
(DNA, CSF, serum) are welcome. We have established a cohort which allows for integration
of multiple clinical data with biomarkers and lifestyle factors. The details about the study are

1
2
3 accessible on www.cbass.cz. We encourage collaborations with researchers from other cohort
4
5 studies with similar aspects to increase sample size.
6

7 **Data sharing:** Data are available upon reasonable request. All proposals for specific analyses
8
9 are reviewed by a scientific committee. Data ownership remains with the center that obtained
10
11 the data originally. Inquiries about the data sharing from the CBAS database, data re-use or
12
13 biospecimen can be addressed to the corresponding author and/or the Principal Investigator
14
15 through email: sheardova@fnusa.cz, jakub.hort@fnmotol.cz
16
17
18
19

20 **References**

- 21
22 1. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative
23
24 integration of the literature. *Acta Psychiatr Scand* 1987;76(5):465–479. doi: 10.1111/j.1600-
25
26 0447.1987.tb02906.x
27
28
- 29
30 2. Kukull WA, Ganguli M. Epidemiology of dementia: concepts and overview. *Neurol Clin*
31
32 2000;18(4):923–950. doi: 10.1016/S0733-8619(05)70233-4
33
- 34
35 3. Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of
36
37 dementia in individuals aged 65 years and older from three geographical areas of England:
38
39 results of the Cognitive Function and Ageing Study I and II. *Lancet* 2013;382(9902):1405–
40
41 1412. doi: 10.1016/S0140-6736(13)61570-6
42
- 43
44 4. Qiu C, von Strauss E, Bäckman L, et al. Twenty-year changes in dementia occurrence
45
46 suggest decreasing incidence in central Stockholm, Sweden. *Neurology* 2013;80(20):1888–
47
48 1894. doi: 10.1212/WNL.0b013e318292a2f9
49
- 50
51 5. Cifkova R, Skodova Z. Longitudinal trends in major cardiovascular disease risk factors in
52
53 the Czech population. *Cas Lek Cesk*. 2004;143(4):219-26.
54
- 55
56 6. Pajak A, Kozela M. Cardiovascular Disease in Central and East Europe. *Public Health*
57
58 *Reviews* 2012; 33(2):416–435. doi: 10.1007/BF03391644
59
60

- 1
2
3 7. Sheardova K, Hort J, Rektorova I, et al. Dementia Diagnosis and Treatment in Czech
4
5 Neurological and Psychiatric Practices. *Cesk Slov Neurol N* 2012;75(2):208–211.
6
- 7
8 8. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due
9
10 to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's
11
12 Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*
13
14 2011;7(3):270–279. doi: 10.1016/j.jalz.2011.03.008
15
- 16
17 9. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric
18
19 depression screening scale: a preliminary report. *J Psychiatr Res* 1983;17(1):37–49. doi:
20
21 10.1016/0022-3956(82)90033-4
22
- 23
24 10. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS Guidelines on the diagnosis and
25
26 management of disorders associated with dementia. *Eur J Neurol* 2012;19(9):1159–79. doi:
27
28 10.1111/j.1468-1331.2012.03784
29
- 30
31 11. Weintraub S, Salmon D, Mercaldo N, et al. The Alzheimer's Disease Centers' Uniform
32
33 Data Set (UDS): the neuropsychologic test battery. *Alzheimer Dis Assoc Disord*
34
35 2009;23(2):91–101. doi: 10.1097/WAD.0b013e318191c7dd
36
- 37
38 12. Nikolai T, Stepankova H, Kopecek M, et al. The Uniform Data Set, Czech Version:
39
40 Normative Data in Older Adults from an International Perspective. *J Alzheimers Dis*
41
42 2018;61(3):1233–1240. doi: 10.3233/JAD-170595
43
- 44
45 13. Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the
46
47 human cerebral cortex on MRI scans into gyral based regions of interest. *Neuroimage*
48
49 2006;31(3):968–980. doi: 10.1016/j.neuroimage.2006.01.021
50
- 51
52 14. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of
53
54 neuroanatomical structures in the human brain. *Neuron* 2002;33(3):341–355. doi:
55
56 10.1016/S0896-6273(02)00569-X
57
58
59
60

- 1
2
3 15. Reuter M, Schmansky NJ, Rosas HD, et al. Within-subject template estimation for
4 unbiased longitudinal image analysis. *Neuroimage* 2012;61(4):1402–1418. doi:
5
6 10.1016/j.neuroimage.2012.02.084
7
8
9
10 16. Nedelska Z, Andel R, Laczó J, et al. Spatial navigation impairment is proportional to right
11 hippocampal volume. *Proc Natl Acad Sci U S A* 2012;109(7):2590–2594. doi:
12
13 10.1073/pnas.1121588109
14
15
16
17 17. Horinek D, Petrovický P, Hort J, et al. Amygdalar volume and psychiatric symptoms in
18 Alzheimer's disease: an MRI analysis. *Acta Neurol Scand* 2006;113(1):40–45. doi:
19
20 10.1111/j.1600-0404.2006.00540
21
22
23
24 18. Kerbler GM, Nedelska Z, Fripp J, et al. Basal Forebrain Atrophy Contributes to
25 Allocentric Navigation Impairment in Alzheimer's Disease Patients. *Front Aging Neurosci*
26
27 2015;7:185. doi: 10.3389/fnagi.2015.00185
28
29
30
31 19. Nelson HE. The National Adult Reading Test (NART): test manual. Windsor: NFER-
32 Nelson 1982.
33
34
35
36 20. Topinková E, Jiráček R, Kožený J. Krátká neurokognitivní baterie pro screening demence v
37 klinické praxi: sedmiminutový screeningový test. *Neurol. pro Praxi* 2002;6: 323–328.
38
39
40 21. Bezdíček O, Štěpánková H, Moták L, et al. Czech version of Rey Auditory Verbal
41 Learning test: normative data. *Neuropsychol Dev Cogn B Aging Neuropsychol Cogn*
42
43 2014;21(6):693–721. doi: 10.1080/13825585.2013.865699
44
45
46
47 22. Benedict RHB, Schretlen D, Groninger L, et al. Revision of the brief visuospatial memory
48 test: Studies of normal performance, reliability, and validity. *Psychological Assessment*
49
50 1996;8(2):145–153. doi: 10.1037/1040-3590.8.2.145
51
52
53
54 23. Meyers JE, Meyers KR. Rey Complex Figure Test and Recognition Trial: Professional
55 manual. Odessa, FL: Psychological Assessment Resources 1995.
56
57
58
59
60

- 1
2
3 24. Bezdicek O, Lukavsky J, Stepankova H, et al. The Prague Stroop Test: Normative
4 standards in older Czech adults and discriminative validity for mild cognitive impairment in
5 Parkinson's disease. *J Clin Exp Neuropsychol* 2015;37(8):794–807. doi:
6
7 10.1080/13803395.2015.1057106
8
9
10
11
12 25. Wechsler D. WAIS-III - Wechslerova inteligenční škála pro dospělé. Praha: Hogrefe–
13 Testcentrum 2010.
14
15
16
17 26. Loonstra AS, Tarlow AR, Sellers AH. COWAT metanorms across age, education, and
18 gender. *Appl Neuropsychol* 2001;8(3):161–166. doi: 10.1207/S15324826AN0803_5
19
20
21 27. Mazancova AF, Nikolai T, Stepankova H, et al. The Reliability of Clock Drawing Test
22 Scoring Systems Modeled on the Normative Data in Healthy Aging and Nonamnesic Mild
23 Cognitive Impairment. *Assessment* 2017;24(7):945–957. doi: 10.1177/1073191116632586
24
25
26
27
28 28. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules.
29 *Neurology* 1993;43:2412–2414. doi: 10.1212/WNL.43.11.2412-a
30
31
32
33 29. Pfeffer RI, Kurosaki TT, Harrah CH, et al. Measurement of functional activities in older
34 adults in the community. *J Gerontol* 1982;37(3):323–329. doi: 10.1093/geronj/37.3.323
35
36
37
38 30. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety:
39 psychometric properties. *J Consult Clin Psychol* 1988;56(6):893–897. doi: 10.1037/0022-
40 006X.56.6.893
41
42
43
44 31. Thomas-Antérion C, Ribas C, Honoré-Masson S, et al. Le questionnaire de plainte
45 mnésique (QPC): un outil de recherche de plainte suspecte d'évoquer une maladie
46 d'Alzheimer. *L'Année Gérontologique* 2003;17(1):56–65.
47
48
49
50
51 32. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual
52 physical activity in epidemiological studies. *Am J Clin Nutr* 1982;36(5):936–42. doi:
53 10.1093/ajcn/36.5.936
54
55
56
57
58
59
60

- 1
2
3 33. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness
4 scale. *Sleep* 1991;14(6):540–545. doi: 10.1093/sleep/14.6.540
5
6
7 34. Reguli Z, Svobodová L. Czech version of the diagnosis of fear of falls in seniors - FES-I
8 (Falls Efficacy Scale International). *Studia Sportiva* 2011;5(2):5–12.
9
10
11 35. Hort J, Laczó J, Vyhnalek M, et al. Spatial navigation deficit in amnesic mild cognitive
12 impairment. *Proc Natl Acad Sci U S A* 2007;104(10):4042–4047. doi:
13 10.1073/pnas.0611314104
14
15
16 36. Laczó J, Vlcek K, Vyhnalek M, et al. Spatial navigation testing discriminates two types of
17 amnesic mild cognitive impairment. *Behav Brain Res* 2009;202(2):252–259. doi:
18 10.1016/j.bbr.2009.03.041
19
20
21 37. Laczó J, Andel R, Vyhnalek M, et al. From morris water maze to computer tests in the
22 prediction of Alzheimer's disease. *Neurodegener Dis* 2012;10(1–4):153–157. doi:
23 10.1159/000333121
24
25
26 38. Varjassyová A, Hořínek D, Andel R, et al. Recognition of Facial Emotional Expression in
27 Amnesic Mild Cognitive Impairment. *J Alzheimers Dis* 2013;33(1):273–280. doi:
28 10.3233/JAD-2012-120148
29
30
31 39. Keane J, Calder AJ, Hodges JR, et al. Face and emotion processing in frontal variant
32 frontotemporal dementia. *Neuropsychologia* 2002;40(6):655–665. doi: 10.1016/S0028-
33 3932(01)00156-7
34
35
36 40. Papp KV, Amariglio RE, Dekhytar M, et al. Development of a psychometrically
37 equivalent short form of the Face-Name Associative Memory Exam for use along the early
38 Alzheimer's disease trajectory. *Clin Neuropsychol* 2014;28(5):771–785. doi:
39 10.1080/13854046.2014.911351
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 41. Buschke H, Mowrey WB, Ramratan WS, et al. Memory Binding Test Distinguishes
4
5 Amnestic Mild Cognitive Impairment and Dementia from Cognitively Normal Elderly. *Arch*
6
7 *Clin Neuropsychol* 2017;32(1):29–39. doi: 10.1093/arclin/acw083
8
9
10 42. Holden HM, Hoebel C, Loftis K, et al. Spatial pattern separation in cognitively normal
11
12 young and older adults. *Hippocampus* 2012;22(9):1826–1832. doi: 10.1002/hipo.22017
13
14 43. Sheardova K, Laczó J, Vyhnalek M, et al. Famous landmark identification in amnestic
15
16 mild cognitive impairment and Alzheimer's disease. *PLoS One* 2014;9(8). doi:
17
18 10.1371/journal.pone.0105623
19
20
21 44. Vlcek K, Laczó J, Vajnerová O, et al. Spatial navigation and episodic-memory tests in
22
23 screening of dementia. *Psychiatrie* 2006;10:35–38.
24
25
26 45. Marková H, Laczó J, Andel R, et al. Perspective taking abilities in amnestic mild
27
28 cognitive impairment and Alzheimer's disease. *Behav Brain Res* 2015;281:229–38. doi:
29
30 10.1016/j.bbr.2014.12.033
31
32
33 46. Gomez R, Fisher JW. Domains of spiritual well-being and development and validation of
34
35 the Spiritual Well-Being Questionnaire. *Pers Individ Dif* 2003;35(8):1975–1991. doi:
36
37 10.1016/S0191-8869(03)00045-X
38
39
40 47. OPD Working Group. Operationalized Psychodynamic Diagnostics: Foundations and
41
42 Manual. Hogrefe & Huber Pub 2001.
43
44
45 48. Vanderstichele H, Bibl M, Engelborghs S, et al. Standardization of preanalytical aspects
46
47 of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper
48
49 from the Alzheimer's Biomarkers Standardization Initiative. *Alzheimers Dement*
50
51 2012;8(1):65–73. doi: 10.1016/j.jalz.2011.07.004
52
53
54 49. Hort J, Glosova L, Vyhnalek M, et al. The liquor tau protein and beta amyloid in
55
56 Alzheimer's disease. *Cesk Slov Neurol N* 2007;70(1):30–36.
57
58
59
60

- 1
2
3 50. Cerman J, Andel R, Laczó J, et al. Subjective Spatial Navigation Complaints - A Frequent
4
5 Symptom Reported by Patients with Subjective Cognitive Decline, Mild Cognitive
6
7 Impairment and Alzheimer's Disease. *Curr Alzheimer Res* 2018;15(3):219–228. doi:
8
9 10.2174/1567205014666171120145349
10
11
12 51. Parizkova M, Lerch O, Moffat SD, et al. The effect of Alzheimer's disease on spatial
13
14 navigation strategies. *Neurobiol Aging* 2018; 64:107-115. doi:
15
16 10.1016/j.neurobiolaging.2017.12.019
17
18 52. Mokrisova I, Laczó J, Andel R, et al. Real-space path integration is impaired in
19
20 Alzheimer's disease and mild cognitive impairment. *Behav Brain Res* 2016;307:150–158. doi:
21
22 10.1016/j.bbr.2016.03.052
23
24 53. Laczó J, Andel R, Nedelska Z, et al. Exploring the contribution of spatial navigation to
25
26 cognitive functioning in older adults. *Neurobiol Aging* 2017;51:67–70. doi:
27
28 10.1016/j.neurobiolaging.2016.12.003
29
30
31 54. Hort J, Andel R, Mokrisova I, et al. Effect of Donepezil in Alzheimer Disease Can Be
32
33 Measured by a Computerized Human Analog of the Morris Water Maze. *Neurodegener Dis*
34
35 2014;13(2–3):192–196. doi: 10.1159/000355517
36
37
38 55. Wu YF, Wu WB, Liu QP, et al. Presence of lacunar infarctions is associated with the
39
40 spatial navigation impairment in patients with mild cognitive impairment: a DTI study.
41
42 *Oncotarget* 2016;7(48):78310-78319. doi: 10.18632/oncotarget.13409.
43
44
45 56. Cerman J, Laczó J, Vyhnalek M, et al. Differences in spatial navigation impairment in
46
47 neurodegenerative dementias. *Cesk. Slov. Neurol* 2014 N; 77/110 (4): 449–455.
48
49
50 57. Laczó J, Andel R, Vyhnalek M, et al. APOE and spatial navigation in amnesic MCI:
51
52 results from a computer-based test. *Neuropsychology* 2014;28(5):676–684. doi:
53
54 10.1037/neu0000072
55
56
57
58
59
60


- 1
2
3 58. Laczó J, Andel R, Vyhnaček M, et al. The effect of TOMM40 on spatial navigation in
4
5 amnesic mild cognitive impairment. *Neurobiol Aging* 2015;36(6):2024–2033. doi:
6
7 10.1016/j.neurobiolaging.2015.03.004
8
9
10 59. Parizková M, Andel R, Lerch O, et al. Homocysteine and Real-Space Navigation
11
12 Performance among Non-Demented Older Adults. *J Alzheimers Dis* 2017;55(3):951–964. doi:
13
14 10.3233/JAD-160667
15
16
17 60. Vyhnaček M, Nikolai T, Andel R, et al. Neuropsychological Correlates of Hippocampal
18
19 Atrophy in Memory Testing in Nondemented Older Adults. *J Alzheimers Dis* 2014;42(3):81–
20
21 90. doi: 10.3233/JAD-132642
22
23
24 61. Sheardová K, Nedelská Z, Šumec R, et al. The effect of spiritual well-being
25
26 (transcendental and non-transcendental domain) on regional brain atrophy in non-demented
27
28 subjects with memory complaints: 3-year follow up data from the Czech Brain Aging Study
29
30 [abstract]. *Alzheimers Dement* 2018; 14(Suppl 7):P587–P588. doi:
31
32 <https://doi.org/10.1016/j.jalz.2018.06.654>
33
34
35 62. Chantí-Ketterl M, Andel R, Lerch O, et al. Cholesterol and cognitive performance among
36
37 community volunteers from the Czech Republic. *Int Psychogeriatr* 2015;27(12):2087–2095.
38
39 doi: 10.1017/S1041610215000320
40
41
42 63. Pappas C, Small BJ, Andel R, et al. Blood Glucose Levels May Exacerbate Executive
43
44 Function Deficits in Older Adults with Cognitive Impairment. *J Alzheimers Dis* 2019;
45
46 67(1):81–89. doi: 10.3233/JAD-180693
47
48
49 64. Šumec R, Sheardová K, Marciniak R, et al. Meditation's impact on cognitive functions in
50
51 mild cognitive impairment: A pilot study. *Biomed Pap Med Fac Univ Palacký Olomouc*
52
53 *Czech Repub* 2017;161(1):54–56.
54
55
56
57
58
59
60

- 1
2
3 65. Tillmann T, Pikhart H, Peasey A, et al. Psychosocial and socioeconomic determinants of
4 cardiovascular mortality in Eastern Europe: A multicentre prospective cohort study. *PLoS*
5
6
7 *Med* 2017;14(12):e1002459. doi: 10.1371/journal.pmed.1002459
8
9
10 66. Brayne C, Davis D. Making Alzheimer's and dementia research fit for populations. *Lancet*
11
12 2012;380(9851):1441–1443. doi: 10.1016/S0140-6736(12)61803-0.
13
14 67. Sachdev PS, Lipnicki DM, Kochan NA, et al. The Prevalence of Mild Cognitive
15
16 Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration.
17
18 *PLoS One* 2015;10(11):e0142388. doi: 10.1371/journal.pone.0142388
19
20
21

22 **Figure legends:**

23
24 Figure 1 The frequency of vascular risk factors in CBAS cohort
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Vascular risk factors frequency in CBAS cohort (%)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

STROBE (Strengthening The Reporting of OBServational Studies in Epidemiology) Checklist

A checklist of items that should be included in reports of observational studies. You must report the page number in your manuscript where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript accordingly before submitting or note N/A.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

Section and Item	Item No.	Recommendation	Reported on Page No.
Title and Abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	
Introduction			
Background/Rationale	2	Explain the scientific background and rationale for the investigation being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	
Methods			
Study Design	4	Present key elements of study design early in the paper	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	

Section and Item	Item No.	Recommendation	Reported on Page No.
Data Sources/ Measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	
Study Size	10	Explain how the study size was arrived at	
Quantitative Variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical Methods	12	(a) Describe all statistical methods, including those used to control for confounding	
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive Data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome Data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	

Section and Item	Item No.	Recommendation	Reported on Page No.
Main Results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other Analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key Results	18	Summarise key results with reference to study objectives	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	
Other Information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this checklist as part of the main manuscript document. It must be uploaded as a separate file.

BMJ Open

Cohort Profile: "The Czech Brain Aging Study (CBAS) – prospective multicenter cohort study on risk and protective factors for dementia in the Czech Republic"

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030379.R3
Article Type:	Cohort profile
Date Submitted by the Author:	10-Nov-2019
Complete List of Authors:	Sheardova, Katerina; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice u svate Anny v Brne, NEUROLOGY DEPARTMENT Vyhnaek, Martin; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Nedelska, Zuzana; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Laczo, Jan; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Andel, Ross; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; University of South Florida, School of Aging Studies Marciniak, Rafal; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center Cerman, Jiri; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Lerch, Ondrej; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology Hort, Jakub; Fakultní nemocnice u Svate Anny v Brně, International Clinical Research Center; Fakultní Nemocnice v Motole, Memory Clinic, Department of Neurology
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Mental health, Public health, Neurology
Keywords:	Dementia < NEUROLOGY, EPIDEMIOLOGY, MENTAL HEALTH

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3 **Cohort Profile: “The Czech Brain Aging Study (CBAS) – prospective multicenter cohort**
4 **study on risk and protective factors for dementia in the Czech Republic”**
5
6
7

8
9 Katerina Sheardova^{1,2} *, Martin Vyhnalek^{1,3}, Zuzana Nedelska^{1,3}, Jan Laczko^{1,3}, Ross Andel^{1,4},
10
11 Rafal Marciniak^{1,2}, Jiri Cerman^{1,3}, Ondrej Lerch^{1,3}, Jakub Hort^{1,3}
12
13

14
15 ¹International Clinical Research Center, St. Anne’s University Hospital, Brno, Czech
16
17 Republic
18

19 ²Department of Neurology, St. Anne’s University Hospital, Brno, Czech Republic
20

21 ³Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and
22
23 Motol University Hospital, Prague, Czech Republic
24

25
26 ⁴School of Aging Studies, University of South Florida, Tampa, USA
27
28
29
30
31
32

33 Corresponding author:
34

35 Katerina Sheardova, MD,
36

37 International Clinical Research Center
38

39 Fakultní nemocnice u Svaté Anny v Brně
40

41 Pekarska 53, 656 91 Brno, Czech Republic
42

43 e-mail.: ksheardova@gmail.com
44

45
46 Phone: +420603198029
47
48
49
50
51

52 Word count 3 982
53
54
55
56
57
58
59
60

ABSTRACT

Purpose: Identification of demographic, physical/physiological, lifestyle, and genetic factors contributing to the onset of dementia specifically, Alzheimer disease (AD), and implementation of novel methods for early diagnosis are important to alleviate prevalence of dementia globally. The Czech Brain Aging Study (CBAS) is the first large, prospective study to address these issues in Central/Eastern Europe by enrolling non-demented adults aged 55+, collecting a variety of personal and biological measures, and tracking cognitive function over time.

Participants: The CBAS recruitment was initiated in 2011 from memory clinics at Brno and Prague University Hospitals, and by end of 2018, the study included 1228 participants. Annual follow-ups include collection of socioeconomic, lifestyle and personal history information, neurology, neuropsychology, laboratory, vital sign and brain MRI data. In a subset, biomarker assessment (CSF, amyloid PET) and spatial navigation are performed. Participants are 69.7 ± 8.1 years old, have 14.6 ± 3.3 years of education at baseline, and 59% are women. By the end of 2018, 31% finished 3 and more years of follow-up, 9% converted to dementia. APOE status is available from 95% of participants. Biological sample bank linked to CBAS database contains CSF, serum and DNA.

Findings to date: Overall, the findings, mainly from cross-sectional analyses, indicate that spatial navigation is a promising marker of early AD and that it can be distinguished from other cognitive functions. Specificity of several standard memory tests for early AD pathology was assessed with implications for clinical practice. The relationship of various lifestyle factors to cognition and brain atrophy was reported.

Future plans: Recruitment is on-going with secured funding. Longitudinal data analyses are currently being conducted. Proposals for collaboration on specific data from the database or

1
2
3 biospecimen, as well as collaborations with similar cohort studies to increase sample size, are
4
5 welcome. Study details are available at www.cbac.cz.
6
7
8
9
10

11
12 Key words: Dementia, epidemiology, mental health
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STRENGTHS AND LIMITATIONS OF THE STUDY:

- CBAS is a prospective longitudinal study of cognitive and brain aging that combines prospective data on lifestyle, genetic, neuropsychological, social, physical and biological factors with neuropsychological and imaging data in the context of AD biomarkers.
- Although biomarkers are available for most cognitively impaired participants, only a subsample of participants with subjective memory complaints and cognitively normal controls has biomarkers available.
- Participants come from university hospital-based memory clinics from two major Czech cities—Brno and Prague—which limits generalizability, although universal health care coverage promotes university hospital visits by a more diverse patient population with respect to urban/rural living and socioeconomic status.
- CBAS has the potential to serve as a crucial, comprehensive source of information about markers of cognitive decline and impairment and can represent a model for studying risk/protective factors for AD in other Central and Eastern European countries.

INTRODUCTION

A gradual increase in the prevalence of dementia has been one of the trends accompanying the growth in life expectancy seen across the globe over the past few decades. Dementia affects 1% of those 60 to 65 years of age and about 45% of those aged 90–95 years,[1, 2] although there is also evidence suggesting that the prevalence as well as incidence of dementia has decreased in the last decade.[3, 4]. This downwards trend may be the result of treatment of hypertension and diabetes as well as greater attention to lifestyle factors stemming from the

1
2
3 increasing awareness of its impact on cognitive and overall health among the general public.
4
5 Still dementia remains a major public health issue. Currently, the course of dementia can only
6
7 be modified by symptomatic therapies and no causal treatment for its most common form,
8
9 Alzheimer disease (AD), or for other neurodegenerative disorders is available. A crucial step
10
11 in an effective management of dementia including AD is to better understand the underlying
12
13 neuropathological mechanisms and the differences in ethnic and lifestyle risk factors. An
14
15 important effort in this context involves the identification of the extent to which demographic,
16
17 physical/physiological, lifestyle, and genetic factors contribute to the onset of dementia and
18
19 AD specifically.
20
21
22

23
24 A parallel effort to searching for risk factors includes early identification of cognitive
25
26 impairment. To further alleviate dementia incidence on the global level, novel diagnostic
27
28 methods need to be implemented to define the risk factors for conversion from preclinical to
29
30 early symptomatic (prodromal) stage and to dementia. Presumably, an early, accurate
31
32 diagnosis is a crucial, yet still elusive, step in the pursuit of effective treatments for dementia.
33
34

35
36 The Czech Brain Aging Study (CBAS) is the first large, prospective study to address these
37
38 issues in Eastern Europe. CBAS was designed to study potential early biomarkers and
39
40 risk/protective factors of cognitive decline and dementia by enrolling a large number of older
41
42 adults, collecting a variety of information about personal and family history, past and current
43
44 lifestyle, genetic, physical and biological measures, and tracking cognitive function and status
45
46 and brain MRI of the participants over time. Czech Republic (CR) has approximately 150,000
47
48 patients with dementia among its roughly 10.6 million inhabitants. CR, like other Eastern
49
50 European countries, is unique in a number of ways including a relatively high prevalence of
51
52 cardiovascular issues. However, since the 1980s, the frequency of common vascular risk
53
54 factors is continuously decreasing, and the mortality associated with vascular risk factors in
55
56 CR and neighboring countries such as Poland has been significantly lower compared to other
57
58
59
60

1
2
3 Eastern European countries, such as Russia. Although the cause of this remains mainly
4 unexplained improved prevention and education are especially suggested.[5, 6]

7 Another unique feature of health care delivery in the CR is a care delivery system that favors
8 memory clinic visits from a wide spectrum of the patient population. In turn, prodromal stages
9 of the disease are mostly handled by neurologists, whereas post-diagnostic patients are more
10 often seen by geriatricians and psychiatrists.[7] Neurologists generally tend to employ more
11 sophisticated diagnostic tools for detecting early stages of cognitive deficit and assessment of
12 its etiology than psychiatrists/geriatricians.

13 Building on this model, CBAS was established using recruitment from two memory clinics at
14 two independent neurology departments based at university hospitals in Prague and Brno,
15 respectively. Data collection started 2005 in Prague and the extension to a multicenter design
16 was possible in 2011 thanks to the European Union Regional Development Fund. The main
17 aim of both memory clinics is to diagnose and treat neurological disorders that lead to
18 cognitive disorders and dementia. Both centers are harmonized in terms of
19 neuropsychological battery, multimodality magnetic resonance imaging (MRI), PET imaging,
20 genetic testing, blood tests and cerebrospinal fluid (CSF) analysis, the set of questionnaires,
21 and a participant database system.

22 Although CBAS lacks the advantages of a population-based study, it uses the only currently
23 feasible design for this type of study in the CR. In addition, it provides access to a relatively
24 large number of clinical patients. A population-based study would need to include much
25 larger numbers to recruit the same number of at-risk patients, which would deem the study
26 unfeasible under the current funding mechanisms.

27 The overarching objectives of CBAS are to help understand lifestyle, genetic, and biological
28 factors influencing variability in the onset of cognitive impairment including AD and finding
29 novel ways of early AD diagnosis. The specific aims are: 1. Exploring epidemiological risk
30

1
2
3 factors for cognitive decline and dementia in the CR; 2. Evaluation of spatial navigation and
4 other experimental neuropsychological tests as early markers of AD pathology; 3. Defining
5 structural, metabolic and functional biomarkers of neurodegenerative diseases in older adults;
6 and 4. Exploring non-pharmacological interventions in prevention of cognitive decline.
7
8
9
10
11

12 **COHORT DESCRIPTION**

14 **Settings**

15
16 CBAS is a prospective longitudinal memory clinic based multi-center study recruiting non-
17 demented adults 55+ years of age. Both CBAS centers work as a low threshold facility; hence
18 the participants are mostly volunteers who come as a self-referral with memory complaints
19 expressed by themselves or the family or who were referred by general practitioners, local
20 specialists or the Czech Alzheimer Society to one of the memory clinics.
21
22
23
24
25
26
27

28 **Eligibility Criteria**

29
30 All participants entering the two memory clinics undergo neurological examination, brain CT
31 or MRI, and cognitive assessment, excluding subjects with dementia. All non-demented
32 subjects aged 55+ years who are able to undergo MRI examination and are eligible (see
33 exclusion criteria below) are initially offered to participate in CBAS. About 95% of these
34 subjects agreed to enter the study. The additional exclusion criteria are severe depression
35 (participants with a recent bout of mild depression are included), a diagnosis of neurological
36 or other psychiatric disorder, a systemic condition potentially causing cognitive impairment,
37 or a recent history of stroke. Participants referred for newly developed cognitive complaints in
38 whom no objective cognitive deficit is found are categorized as subjective cognitive decline
39 (SCD). Participants with objective cognitive decline are classified as mild cognitive
40 impairment (MCI) based on 2011 NIA-AA guidelines by Albert and colleagues.[8]
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

clinical interview and with no objective cognitive deficit, are recruited from adults taking continuing education classes under the University of the Third Age at Charles University and from relatives of employees or of study participants.

Written informed consent was obtained from each participant prior to entering the study. The Ethics Committees of Motol University Hospital and St. Anne's University Hospital approved the study.

Cohort Characteristics

Between January 2011 and December 2018, 1228 subjects who fulfilled the CBAS criteria agreed to enter the study. Brno has contributed 496 and Prague 732 participants so far, with enrollment accelerated at both sites more recently. The basic characteristics of this cohort are presented in table 1, the frequency of vascular risk factors is in figure 1. The frequencies of these vascular risk factors in CBAS are similar to national reports and studies, almost solely conducted by cardiologists and internal medicine specialists in CR,[5] although the proportion of smokers is lower in CBAS compared to national average reported in 2004.

Table 1. Basic characteristics of the CBAS cohort at baseline

	Total			SCD			MCI			NC		
	mean (SD) or ratio	median or %	Inter quartile range	mean (SD) or ratio	median or %	Inter quartile range	mean (SD) or ratio	median or %	Inter quartile range	mean (SD) or ratio	median or %	Inter quartile range
No. of participants	1228			428			732			68		
Gender (M/F)	502/726	40.9%M		146/282	34.1%M		329/403	44.9%M		27/41	39.7%M	
Age/years	69.7 (8.0)	70	64-75	67.1 (7.9)	66	61-72	71.2 (7.9)	72	66-77	68.9 (7.1)	69	64-73
Education/years	14.6 (3.3)	14	12-17	15.2 (3.0)	15	13-18	14.3 (3.4)	13	12-17	16.1 (3.4)	16	13-17
Depression (GDS)	3.86 (3.1)	3	2-5	3.9 (3.0)	3	2-5	4.0 (3.2)	3	2-6	1.6 (1.3)	1	0-1

Notes: SD = standard deviation; GDS = Geriatric Depression Scale[9]

Apolipoprotein E4 (APOE; and its $\epsilon 4$ allele, specifically) is the strongest genetic risk factor for late onset AD, and is associated with impairments in cerebral metabolism and cerebrovascular function. About 30% of the participants carry at least one APOE $\epsilon 4$ allele.

The dataset includes 15.2% of APOE $\epsilon 4$ allele heterozygotes and 5.4% homozygotes in MCI

1
2
3 subjects, 7.2% heterozygotes and 2.1% homozygotes in SCD subjects and only 1.2%
4
5 heterozygotes in NC subjects. About 25% of the subjects are living alone and the rest are
6
7 living with a spouse, friend, or a family member. All participants are community dwelling.
8
9
10 The age of the cohort reflects the age distribution of older adults in the CR, with 12% of the
11
12 subjects 80+ years of age, and 4% 85+ years of age at baseline. There are 3.3 million people
13
14 aged 55+ living in the CR, 12% of whom are 80+ and 6% are 85+ according to the 2018
15
16 Czech Census data. Education of our cohort is slightly higher than the average education level
17
18 of 55+ population in the CR; 7.3% of the CBAS participants finished basic education (vs.
19
20 26% in the CR), 68% finished secondary (high school) education (vs. 62% in the CR) and
21
22 48% achieved college/university degree (vs. 9% in the CR). Efforts are under way to recruit a
23
24 more diverse cohort.
25
26
27

28
29 Aside from the CBAS cohort defined above, the “CBAS Plus” database is also available,
30
31 containing baseline data from 155 Brno and 283 Prague subjects who did not meet the CBAS
32
33 inclusion criteria due to mild dementia of various neurodegenerative origin, depression,
34
35 history of stroke etc. and who signed informed consent. Dementia etiology (AD dementia,
36
37 frontotemporal lobar degeneration, Parkinsonian syndromes, vascular disorders etc.) is
38
39 diagnosed according to established guidelines.[10] The CBAS Plus cohort reflects a real
40
41 memory clinic patient profile and therefore can provide clinically relevant and important data
42
43 about a wide spectrum of neurological brain diseases leading to dementia and the role of
44
45 vascular risk factors and psychiatric co-morbidity.
46
47
48

49 **Methods**

50
51 At each visit, all study participants undergo a standard set of procedures. Neurological and
52
53 comprehensive neuropsychology examination including Uniform Data Set (UDS) battery is
54
55 administered;[11, 12] laboratory and vital functions assessments are also performed. Socio-
56
57 demographic, personal, pharmacological and family history data are collected. Participants
58
59
60

and their informants complete multiple questionnaires about cognitive complaints and lifestyle factors. 1.5T or 3T MRI scans are performed every 24 months or earlier when a participant converts to dementia or progresses towards cognitive impairment at an unusual rate. Volumetric MRI is analyzed in all patients to obtain measures of regional cortical thickness and subcortical volumes cross-sectionally and longitudinally using Freesurfer image analysis suite (v5.3; <http://surfer.nmr.mgh.harvard.edu/>). The details of Freesurfer image processing have been published elsewhere,[13-15] including previous studies by our group.[16, 17] A subset of MRI volumes has been previously measured using manual tracing and a subset of participants' MRI volumes is used to measure the atrophy of the cholinergic basal forebrain nuclei.[18] Genotyping is carried out at baseline. In a subset, CSF and/or amyloid PET is performed and additional data are collected from experimental neuropsychology, spatial navigation and personality trait assessment. The detailed procedures including their timelines are presented in table 2.

Table 2. The CBAS Procedures

Frequency	Procedure	Specification
Annually	Clinical exam	Standard complex neurology examination
Annually	Standard neuropsychology	<p>Uniform Data Set[11, 12]: Mini-Mental State Examination, Digit Span Forward and Backward, Digit Symbol, Trail Making Test A and B, Animal list generation, Vegetable list generation, Boston Naming Test (30 odd items), Logical Memory, Story A</p> <p>Premorbid ability estimation: National Adult Reading Test[19]</p> <p>Memory assessment: Enhanced cued recall test,[20] Rey Auditory Verbal Learning Test,[21] Brief Visuospatial Memory Test–Revised,[22] Rey-Osterrieth Complex Figure Test – (ROCFT) recall[23]</p> <p>Executive functions: Prague Stroop test,[24] Similarities (WAIS-R)[25], Controlled Oral Word Association Test[26]</p> <p>Visuoconstruction: Clock Test,[27] ROCFT copy[23]</p> <p>Functional scales: Clinical Dementia Rating scale,[28] Functional assessment questionnaire[29]</p> <p>Symptoms of anxiety and depression: Geriatric Depression Scale (15 items version),[9] Beck Anxiety Inventory[30]</p>

Annually	Laboratory	Fasting glucose, lipid profile, homocysteine, vitamin B12, thyroid hormones, folic acid, renal and liver function, C-reactive protein, glycosylated hemoglobin
Annually	Vital functions	blood pressure, pulse frequency, waist/hips ratio, BMI
Annually	Socio- economic data	Marital status, Type of living, Current occupation
Annually	Questionnaires	Subjective cognitive complaints (QPC),[31] physical/mental activity at midlife and currently, Becke's Habitual Physical Activity[32], Epworth Sleepiness Scale,[33] Falls Self-Efficacy Scale – International[34]
Biannually	MRI	1.5T protocol: plane localizer; standard clinical T2; T1 3-dimensional isometric magnetization-prepared rapid gradient echo(MPRAGE) with isometric voxel; fluid-attenuated inversion recovery(FLAIR); T2*; echoplanar imaging for diffusion tensor imaging with 32directions.3T protocol: plane localizer; standard clinical T1 and T2; T1 3-dimensional isometric magnetization-prepared rapid gradient echo (MPRAGE) with isometric voxel; echoplanar imaging for diffusion tensor imaging with 64 directions; fluid-attenuated inversion recovery (FLAIR); T2 fast spin echo;T2*; resting state functional MRI. Switch to 3T MRI since 2015 in Brno, since 2019 in Prague
At baseline	Demography	Age, education, occupation, laterality
At baseline all Optional	Genotyping	APOE TOMM40, BDNF, CD36, BuChE, KIBRA, TREM2, PSEN 1, PSEN 2, APP, TARDBP, MAPT, GRN, C9orf72
Subset at both centres	CSF	Amyloid β -42, total, tau, p-tau, oligoclonal bands, CSF biochemistry,
Subset at both centres	Amyloid PET	PET/MRI or PET/CT (visual assessment), flutemetamol, dual phase ("perfusion") PET;
Prague cohort all	Spatial navigation[35, 36, 37]	hidden goal task, simple navigation task, path integration task, Y-maze assessment, intersections task, sea hero quest, spatial tasks in virtual reality/augmented virtual reality
Prague cohort optional	Experimental neuropsychology	Facial emotion recognition,[38, 39] Famous faces identification,[39] FNAME 12 items version,[40] Memory binding test,[41] spatial pattern separation task[42] In house developed tests: Famous landmarks identification,[43] episodic-like memory test,[44] Arena Perspective Taking Task[45]
Brno cohort All at baseline	Specific questionnaires	Spiritual well-being questionnaire (SHALOM),[46] Operationalized Psychodynamic Diagnostics OPD-2 (OPD working group),[47] early life trauma assessment

The CBAS is complemented by a biological sample bank linked to data from the CBAS and “CBAS Plus” cohorts. The CSF collection and storage are carried out after signing an informed consent in accordance with the ethical guidelines in the CR and good clinical practice, and according to the widely recognized consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.[48] Eighteen aliquots of 0.2ml CSF and 5-9 aliquots of serum are stored for each participant. All samples are stored at -80C. Commercial ELISA kits (Innogenetics®) are used for dementia biomarker analyses (Aβ1-42, protein tau, and phospho-tau) and cut off values derived from validation study are used.[49] The characteristics of the biobank as of December 2018 are listed in table 3.

Table 3. Biobank characteristics

	Aliquots per patient stored at -80C	No. of participants
CSF	18x0.2ml	75 in Brno/350 in Prague
Serum	5-9x0.5ml	145 in Brno/350 in Prague
DNA	concentration >100 ng/μl	95% of all participants

Follow-up

Participants are examined annually; they are invited for a follow-up via a letter mailed to their permanent address. Subsets of SCDs and NC who are cognitively stable for the first 3 visits are followed every other year. At each follow-up visit, all participants undergo a standard set of procedures described in the Methods section; see table 2 for additional details. Standard criteria-based consensus diagnosis is performed based on each visit. MCI and dementia etiology is based on biomarkers.[8, 10]

Progression from NC/SCD to MCI or to dementia, and from MCI to dementia is the main outcome, along with longitudinal quantitative measures of cognitive performance, which are used for evaluation of early markers of AD and risk factors for progression. Participants are censored when they progress to dementia as ascertained by panel consensus conference or if they can no longer undergo an MRI examination. Between entering the study and the end of

1
2
3 2018, 31% of the total of 1228 participants already completed at least 3 full yearly evaluations
4
5 (baseline + 2 follow up visits) with at least 2 brain MRI sessions. Additionally, 9% of all
6
7 participants converted to dementia at some timepoint within their follow-up and were no
8
9 longer followed, and 16% of the participants were lost to follow-up for various reasons (loss
10
11 of interest, newly acquired MRI intolerance, worsening health condition, change of residence
12
13 address not allowing invitation for follow up, etc.). From all participants recruited by the end
14
15 of 2018, 931 (75%) continue in the study. The recruitment is ongoing with secured funding.
16
17 We have just reached a sufficient number of longitudinally followed participants to begin with
18
19 longitudinal data analyses which will contribute significantly to the fulfillment of most of the
20
21 study aims.
22
23
24
25

26 **Patient and public involvement**

27
28 Patient involvement was crucial in questionnaire implementation. Initial versions of
29
30 questionnaires were consulted with a pilot group of patients and their caregivers. Based on
31
32 their feedback, we excluded McNair's questionnaire of activities of daily living. The
33
34 adaptation of Mild Behaviour impairment checklist was graphically reworked after being
35
36 consulted with our participants increasing the rate of successful completion considerably. In
37
38 the tests developed by our team, such as the Famous Landmark Identification Test[43] or the
39
40 Subjective Spatial Memory Complaints Questionnaire,[50] we consulted our participants
41
42 during the entire development process including the selection of relevant items. Some of the
43
44 items were generated from qualitative research which always preceded the development of
45
46 new questionnaires. These procedures ensured high participation and validity.
47
48
49

50
51 Wider public engagement is ensured by public lectures regularly performed by the CBAS
52
53 team members, which inform the public about the study, its goals and procedures. Partial
54
55 results concerning lifestyle are discussed. The information about the study and the
56
57 possibilities to join are communicated to the public via various channels including the
58
59
60

1
2
3 Concept Alzheimer Café, CBAS webpage, etc. We also closely cooperate with Czech
4
5 Alzheimer Association (CAA) connecting dementia specialists with patients and their
6
7 caregivers. Many CAA members and participants of the study help disseminate information
8
9 about the study which facilitates recruitment.
10

11 **FINDINGS TO DATE**

12
13
14 Data collected from the CBAS and CBAS plus cohorts have spurred more than 60
15
16 publications so far mainly from cross-sectional analyses, primarily in impacted neurology and
17
18 neuroscience journals (the complete list is available at www.cbass.cz). We highlight the most
19
20 significant ones here in the context of the aims of the study.
21
22

23 **Early markers of AD**

24 Spatial navigation

25
26 Spatial navigation testing is part of the baseline CBAS protocol[35, 36] (for details see table
27
28 2). Outcomes of this comprehensive examination have been compared with results of
29
30 structural brain MRI and genetic and laboratory assessment. Our cross-sectional studies using
31
32 clinically and biomarker-defined individuals with AD[51] have shown that spatial navigation
33
34 is a distinct cognitive function and a promising cognitive marker of early stages of AD, the
35
36 assessment of which may add important information to a comprehensive neuropsychological
37
38 profile of individuals in the CBAS study[52, 53] and may be useful for early and differential
39
40 diagnosis of AD, or for evaluating the effect of therapies.[37, 54] Longitudinal study will aim
41
42 to provide evidence for this notion. It should be noted that other co-pathologies may
43
44 negatively impact on spatial navigation performance in individuals with AD.[55, 56]
45
46
47 We have found that impairment of spatial navigation is associated with structural changes of
48
49 the right hippocampus, entorhinal cortex, posterior parietal lobe and basal forebrain, i.e. the
50
51 structures that are impaired very early in AD[16, 18, 52] and that it can be influenced by genetic
52
53 background[57, 58] and cardiovascular risk factors.[59]
54
55
56
57
58
59
60

Experimental neuropsychology

We have shown that our “in-house” developed Famous Landmarks Identification Test, created with the help from our participants, could be useful in recognizing early stages of AD.[43] We have also tested the specificity of several standard memory tests for estimating hippocampal atrophy in the CBAS participants which could have immediate implications for clinical practice.[60]

Lifestyle factors and AD

We have recently completed the first longitudinal MRI analysis from CBAS[61] showing that the level of spiritual well-being can influence the atrophy rates in regions affected by AD pathology, as well as those associated with attention and with behavioral symptoms. The manuscript is being prepared for publication. Previous studies have included examinations of cholesterol[62] and blood glucose[63] in relation to cognitive outcomes.

Non-pharmacological interventions

We have completed an intervention study with mindfulness-based stress reduction (MBSR) therapy and cognitive training in members of CBAS with MCI. We have shown that MBSR is a suitable intervention for subjects with mild cognitive decline[64] and findings regarding its effect on cognition, immunology profile and depression suggest that MBSR could be effective in secondary prevention. The manuscript is submitted for publication.

STRENGTHS AND LIMITATIONS

CBAS represents a unique effort to study cognitive and brain ageing in Central and Eastern Europe. It is a prospective study of a relatively culturally and genetically homogenous Czech population based mainly on recruitment of volunteers who come to a memory clinic in one of the two largest cities in the country - Prague and Brno. The study includes a large biological sample bank (sera, CSF, DNA) that can enhance diagnostic accuracy and improve predictive validity of analyses with other AD risk factors, such as lifestyle factors and vascular risk

1
2
3 factors. Despite several studies on vascular risk factors, the reasons for the high frequency of
4
5 vascular problems in Eastern Europe, as well as the association between vascular factors and
6
7 cognitive performance,[65] remain poorly understood. We believe that data from our study
8
9 can contribute important information on this topic.

10
11
12 The study also has limitations. While having two sites involved in participant recruitment is
13
14 an advantage, it doesn't create population representation. Although it is also of note that due
15
16 to the nature of health care delivery in the CR, attendance at the two memory clinics is far
17
18 from restricted to the close geographical proximity. Rather, older adults of all ages and
19
20 backgrounds visit the clinics from a variety of geographical areas. This could increase the bias
21
22 as usually it is the least deprived that access tertiary expertise in most health care settings.
23
24 Therefore, coding of demographics and participant residence (urban vs rural or by region) can
25
26 enrich analyses and help increase interpretability of any findings, and potentially ameliorate
27
28 this limitation to at least some extent. Given the recruitment from university hospital-based
29
30 clinics, one may assume that the sample could attract relatively young patients.[66] However,
31
32 although the average age for patients with MCI is substantially lower than the UK-based
33
34 Cognitive Function & Ageing Studies, it is roughly similar to studies from Italy, Spain,
35
36 Australia, and studies conducted in Asia.[67] Still, results of longitudinal analyses are likely
37
38 to be affected by selective attrition. Additionally, the current sample is relatively highly
39
40 educated and efforts are under way to recruit participants with more diverse educational
41
42 attainment. However, there are also other advantages to basing recruitment on memory
43
44 clinics, such as the access to much higher rates of at-risk patients than is typical for a
45
46 population-based study, making the recruitment approach crucial in terms of study feasibility
47
48 under the current CBAS funding structure.

49
50
51 Although brain imaging is available for most participants, biomarkers are available only for a
52
53 subsample. Efforts are under way to increase biomarker data availability. Detailed
54
55
56
57
58
59
60

1
2
3 information is missing on subjects lost to follow-up. Despite these limitations, to the best of
4
5 our knowledge, CBAS remains the largest coordinated effort to collect longitudinal data in the
6
7 context of cognitive and brain aging in the Czech Republic and in Eastern Europe in general.
8
9
10 CBAS is also unique in its richness of prospective data on lifestyle, genetic,
11
12 neuropsychological, social, physical and biological factors as predictors of cognitive decline
13
14 in the context of AD biomarkers. Until a population-based study with the same aim can be
15
16 carried out within Eastern Europe, the CBAS may serve as the only source of information
17
18 about a wide variety of risk factors for cognitive impairment in this geographical region.
19
20
21 In conclusion, CBAS has the potential to serve as a crucial, comprehensive source of
22
23 information about markers of cognitive decline and impairment and can represent a model for
24
25 studying risk/protective factors for AD in other Central and Eastern European countries.
26
27

28 **Acknowledgement:**

29
30 All of the CBAS participants and their relatives are appreciated for their involvement in the
31
32 project and their dedication.
33
34

35 We would like to thank the heads of Neurology departments Prof. Petr Marusic from Motol
36
37 University Hospital Prague and Prof. Milan Brazdil from St. Anne's University Hospital Brno
38
39 for their support. Big appreciation to the supporting CBAS team: neurologists and
40
41 psychologists, for thorough data collection, study nurses and coordinators for an excellent
42
43 management of participants and procedures and also to external collaborators: Jitka
44
45 Hanzalova Motol University Hospital, Prague, for laboratory assessment, Vaclav Matoska
46
47 from Homolka Hospital, Prague and T. Freiburger from Cardiovascular and Transplant
48
49 surgery Center Brno for covering the DNA biobank, T. Machulka and S. Belaskova from
50
51 ICRC Brno for database and statistic support. We would also like to thank the teams from
52
53 MRI and PET facilities from University Hospitals in Brno and Prague.
54
55
56
57

58 **FOOTNOTES:**

1
2
3 **Patient consent for publication:** Not required
4

5 **Contributors:** KS, JH, MV, JL and ZN conceived the hypothesis and study design, KS, MV,
6 JL, RM, JC, JH collected the data, OL, ZN, RA provided the data analyses, RA is responsible
7 for statistical analyses. All authors had input on interpretation and reporting of study findings.
8 KS wrote the first draft; all authors reviewed and edited the final version. All authors provided
9 approval for the published version of this manuscript.
10
11
12
13
14
15

16 **Funding:** During 2011-2015, CBAS was supported by the project FNUSA-ICRC [grant
17 number CZ.1.05/1.1.00/02.0123] from the European Regional Development Fund. Between
18 2016-2020, it is supported by National Program of Sustainability II (Ministry of Education,
19 Youth and Sports of the Czech Republic) [grant number LQ1605]. The following grants
20 contributed to specific subprojects based on CBAS: Ministry of Health Internal Grant Agency
21 [grant number NT 11225-4/2010], Czech Health Research Council [grant numbers 16-
22 27611A, NV18-04-00455], Motol University Hospital, Prague, Czech Republic [grant number
23 CZ – DRO 00064203], Institutional Support of Laboratory Research [grant number 2/2012
24 (699002)], Institutional Support of Excellence 2nd Medical Faculty Charles University [grant
25 number 699012], Grant Agency of the Czech Republic [grant numbers 309/05/0693,
26 309/09/1053] and Grant Agency of the Charles University [grant numbers 91007, 74308,
27 98509, 624012, 546113, 1108214, 135215, 654217, 308216, 546317 and 693018].
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Competing interests:** None declared.
46

47 **Provenance and peer review:** Not commissioned; externally peer reviewed.
48

49 **Ethics approval:** The Ethics Committee of Motol University Hospital and St. Anne's
50 University Hospital approved the study.
51
52

53 **Collaboration:** Proposals for collaboration on specific data from the database or biospecimen
54 (DNA, CSF, serum) are welcome. We have established a cohort which allows for integration
55 of multiple clinical data with biomarkers and lifestyle factors. The details about the study are
56
57
58
59
60

1
2
3 accessible on www.cbass.cz. We encourage collaborations with researchers from other cohort
4
5 studies with similar aspects to increase sample size.
6

7 **Data sharing:** Data are available upon reasonable request. All proposals for specific analyses
8
9 are reviewed by a scientific committee. Data ownership remains with the center that obtained
10
11 the data originally. Inquiries about the data sharing from the CBAS database, data re-use or
12
13 biospecimen can be addressed to the corresponding author and/or the Principal Investigator
14
15 through email: sheardova@fnusa.cz, jakub.hort@fnmotol.cz
16
17
18
19

20 **References**

- 21
22 1. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative
23
24 integration of the literature. *Acta Psychiatr Scand* 1987;76(5):465–479. doi: 10.1111/j.1600-
25
26 0447.1987.tb02906.x
27
28
- 29 2. Kukull WA, Ganguli M. Epidemiology of dementia: concepts and overview. *Neurol Clin*
30
31 2000;18(4):923–950. doi: 10.1016/S0733-8619(05)70233-4
32
33
- 34 3. Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of
35
36 dementia in individuals aged 65 years and older from three geographical areas of England:
37
38 results of the Cognitive Function and Ageing Study I and II. *Lancet* 2013;382(9902):1405–
39
40 1412. doi: 10.1016/S0140-6736(13)61570-6
41
42
- 43 4. Qiu C, von Strauss E, Bäckman L, et al. Twenty-year changes in dementia occurrence
44
45 suggest decreasing incidence in central Stockholm, Sweden. *Neurology* 2013;80(20):1888–
46
47 1894. doi: 10.1212/WNL.0b013e318292a2f9
48
49
- 50 5. Cifkova R, Skodova Z. Longitudinal trends in major cardiovascular disease risk factors in
51
52 the Czech population. *Cas Lek Cesk.* 2004;143(4):219-26.
53
54
- 55 6. Pajak A, Kozela M. Cardiovascular Disease in Central and East Europe. *Public Health*
56
57 *Reviews* 2012; 33(2):416–435. doi: 10.1007/BF03391644
58
59
60

- 1
2
3 7. Sheardova K, Hort J, Rektorova I, et al. Dementia Diagnosis and Treatment in Czech
4
5 Neurological and Psychiatric Practices. *Cesk Slov Neurol N* 2012;75(2):208–211.
6
- 7
8 8. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due
9
10 to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's
11
12 Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*
13
14 2011;7(3):270–279. doi: 10.1016/j.jalz.2011.03.008
15
- 16
17 9. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric
18
19 depression screening scale: a preliminary report. *J Psychiatr Res* 1983;17(1):37–49. doi:
20
21 10.1016/0022-3956(82)90033-4
22
- 23
24 10. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS Guidelines on the diagnosis and
25
26 management of disorders associated with dementia. *Eur J Neurol* 2012;19(9):1159–79. doi:
27
28 10.1111/j.1468-1331.2012.03784
29
- 30
31 11. Weintraub S, Salmon D, Mercaldo N, et al. The Alzheimer's Disease Centers' Uniform
32
33 Data Set (UDS): the neuropsychologic test battery. *Alzheimer Dis Assoc Disord*
34
35 2009;23(2):91–101. doi: 10.1097/WAD.0b013e318191c7dd
36
- 37
38 12. Nikolai T, Stepankova H, Kopecek M, et al. The Uniform Data Set, Czech Version:
39
40 Normative Data in Older Adults from an International Perspective. *J Alzheimers Dis*
41
42 2018;61(3):1233–1240. doi: 10.3233/JAD-170595
43
- 44
45 13. Desikan RS, Ségonne F, Fischl B, et al. An automated labeling system for subdividing the
46
47 human cerebral cortex on MRI scans into gyral based regions of interest. *Neuroimage*
48
49 2006;31(3):968–980. doi: 10.1016/j.neuroimage.2006.01.021
50
- 51
52 14. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of
53
54 neuroanatomical structures in the human brain. *Neuron* 2002;33(3):341–355. doi:
55
56 10.1016/S0896-6273(02)00569-X
57
58
59
60

- 1
2
3 15. Reuter M, Schmansky NJ, Rosas HD, et al. Within-subject template estimation for
4 unbiased longitudinal image analysis. *Neuroimage* 2012;61(4):1402–1418. doi:
5
6 10.1016/j.neuroimage.2012.02.084
7
8
9
10 16. Nedelska Z, Andel R, Laczó J, et al. Spatial navigation impairment is proportional to right
11 hippocampal volume. *Proc Natl Acad Sci U S A* 2012;109(7):2590–2594. doi:
12
13 10.1073/pnas.1121588109
14
15
16
17 17. Horinek D, Petrovický P, Hort J, et al. Amygdalar volume and psychiatric symptoms in
18 Alzheimer's disease: an MRI analysis. *Acta Neurol Scand* 2006;113(1):40–45. doi:
19
20 10.1111/j.1600-0404.2006.00540
21
22
23
24 18. Kerbler GM, Nedelska Z, Fripp J, et al. Basal Forebrain Atrophy Contributes to
25 Allocentric Navigation Impairment in Alzheimer's Disease Patients. *Front Aging Neurosci*
26
27 2015;7:185. doi: 10.3389/fnagi.2015.00185
28
29
30
31 19. Nelson HE. The National Adult Reading Test (NART): test manual. Windsor: NFER-
32 Nelson 1982.
33
34
35
36 20. Topinková E, Jiráček R, Kožený J. Krátká neurokognitivní baterie pro screening demence v
37 klinické praxi: sedmiminutový screeningový test. *Neurol. pro Praxi* 2002;6: 323–328.
38
39
40 21. Bezdíček O, Štěpánková H, Moták L, et al. Czech version of Rey Auditory Verbal
41 Learning test: normative data. *Neuropsychol Dev Cogn B Aging Neuropsychol Cogn*
42
43 2014;21(6):693–721. doi: 10.1080/13825585.2013.865699
44
45
46
47 22. Benedict RHB, Schretlen D, Groninger L, et al. Revision of the brief visuospatial memory
48 test: Studies of normal performance, reliability, and validity. *Psychological Assessment*
49
50 1996;8(2):145–153. doi: 10.1037/1040-3590.8.2.145
51
52
53
54 23. Meyers JE, Meyers KR. Rey Complex Figure Test and Recognition Trial: Professional
55 manual. Odessa, FL: Psychological Assessment Resources 1995.
56
57
58
59
60

- 1
2
3 24. Bezdicek O, Lukavsky J, Stepankova H, et al. The Prague Stroop Test: Normative
4 standards in older Czech adults and discriminative validity for mild cognitive impairment in
5 Parkinson's disease. *J Clin Exp Neuropsychol* 2015;37(8):794–807. doi:
6
7 10.1080/13803395.2015.1057106
8
9
10
11
12 25. Wechsler D. WAIS-III - Wechslerova inteligenční škála pro dospělé. Praha: Hogrefe–
13 Testcentrum 2010.
14
15
16
17 26. Loonstra AS, Tarlow AR, Sellers AH. COWAT metanorms across age, education, and
18 gender. *Appl Neuropsychol* 2001;8(3):161–166. doi: 10.1207/S15324826AN0803_5
19
20
21 27. Mazancova AF, Nikolai T, Stepankova H, et al. The Reliability of Clock Drawing Test
22 Scoring Systems Modeled on the Normative Data in Healthy Aging and Nonamnesic Mild
23 Cognitive Impairment. *Assessment* 2017;24(7):945–957. doi: 10.1177/1073191116632586
24
25
26
27
28 28. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules.
29 *Neurology* 1993;43:2412–2414. doi: 10.1212/WNL.43.11.2412-a
30
31
32
33 29. Pfeffer RI, Kurosaki TT, Harrah CH, et al. Measurement of functional activities in older
34 adults in the community. *J Gerontol* 1982;37(3):323–329. doi: 10.1093/geronj/37.3.323
35
36
37
38 30. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety:
39 psychometric properties. *J Consult Clin Psychol* 1988;56(6):893–897. doi: 10.1037/0022-
40 006X.56.6.893
41
42
43
44 31. Thomas-Antérion C, Ribas C, Honoré-Masson S, et al. Le questionnaire de plainte
45 mnésique (QPC): un outil de recherche de plainte suspecte d'évoquer une maladie
46 d'Alzheimer. *L'Année Gérontologique* 2003;17(1):56–65.
47
48
49
50
51 32. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual
52 physical activity in epidemiological studies. *Am J Clin Nutr* 1982;36(5):936–42. doi:
53 10.1093/ajcn/36.5.936
54
55
56
57
58
59
60

- 1
2
3 33. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness
4 scale. *Sleep* 1991;14(6):540–545. doi: 10.1093/sleep/14.6.540
5
6
7 34. Reguli Z, Svobodová L. Czech version of the diagnosis of fear of falls in seniors - FES-I
8 (Falls Efficacy Scale International). *Studia Sportiva* 2011;5(2):5–12.
9
10 35. Hort J, Laczó J, Vyhnalek M, et al. Spatial navigation deficit in amnesic mild cognitive
11 impairment. *Proc Natl Acad Sci U S A* 2007;104(10):4042–4047. doi:
12 10.1073/pnas.0611314104
13
14 36. Laczó J, Vlcek K, Vyhnalek M, et al. Spatial navigation testing discriminates two types of
15 amnesic mild cognitive impairment. *Behav Brain Res* 2009;202(2):252–259. doi:
16 10.1016/j.bbr.2009.03.041
17
18 37. Laczó J, Andel R, Vyhnalek M, et al. From morris water maze to computer tests in the
19 prediction of Alzheimer's disease. *Neurodegener Dis* 2012;10(1–4):153–157. doi:
20 10.1159/000333121
21
22 38. Varjassyová A, Hořínek D, Andel R, et al. Recognition of Facial Emotional Expression in
23 Amnesic Mild Cognitive Impairment. *J Alzheimers Dis* 2013;33(1):273–280. doi:
24 10.3233/JAD-2012-120148
25
26 39. Keane J, Calder AJ, Hodges JR, et al. Face and emotion processing in frontal variant
27 frontotemporal dementia. *Neuropsychologia* 2002;40(6):655–665. doi: 10.1016/S0028-
28 3932(01)00156-7
29
30 40. Papp KV, Amariglio RE, Dekhytar M, et al. Development of a psychometrically
31 equivalent short form of the Face-Name Associative Memory Exam for use along the early
32 Alzheimer's disease trajectory. *Clin Neuropsychol* 2014;28(5):771–785. doi:
33 10.1080/13854046.2014.911351
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 41. Buschke H, Mowrey WB, Ramratan WS, et al. Memory Binding Test Distinguishes
4
5 Amnestic Mild Cognitive Impairment and Dementia from Cognitively Normal Elderly. *Arch*
6
7 *Clin Neuropsychol* 2017;32(1):29–39. doi: 10.1093/arclin/acw083
8
9
10 42. Holden HM, Hoebel C, Loftis K, et al. Spatial pattern separation in cognitively normal
11
12 young and older adults. *Hippocampus* 2012;22(9):1826–1832. doi: 10.1002/hipo.22017
13
14 43. Sheardova K, Laczó J, Vyhnalek M, et al. Famous landmark identification in amnestic
15
16 mild cognitive impairment and Alzheimer's disease. *PLoS One* 2014;9(8). doi:
17
18 10.1371/journal.pone.0105623
19
20
21 44. Vlcek K, Laczó J, Vajnerová O, et al. Spatial navigation and episodic-memory tests in
22
23 screening of dementia. *Psychiatrie* 2006;10:35–38.
24
25
26 45. Marková H, Laczó J, Andel R, et al. Perspective taking abilities in amnestic mild
27
28 cognitive impairment and Alzheimer's disease. *Behav Brain Res* 2015;281:229–38. doi:
29
30 10.1016/j.bbr.2014.12.033
31
32
33 46. Gomez R, Fisher JW. Domains of spiritual well-being and development and validation of
34
35 the Spiritual Well-Being Questionnaire. *Pers Individ Dif* 2003;35(8):1975–1991. doi:
36
37 10.1016/S0191-8869(03)00045-X
38
39
40 47. OPD Working Group. Operationalized Psychodynamic Diagnostics: Foundations and
41
42 Manual. Hogrefe & Huber Pub 2001.
43
44
45 48. Vanderstichele H, Bibl M, Engelborghs S, et al. Standardization of preanalytical aspects
46
47 of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper
48
49 from the Alzheimer's Biomarkers Standardization Initiative. *Alzheimers Dement*
50
51 2012;8(1):65–73. doi: 10.1016/j.jalz.2011.07.004
52
53
54 49. Hort J, Glosova L, Vyhnalek M, et al. The liquor tau protein and beta amyloid in
55
56 Alzheimer's disease. *Cesk Slov Neurol N* 2007;70(1):30–36.
57
58
59
60

- 1
2
3 50. Cerman J, Andel R, Laczó J, et al. Subjective Spatial Navigation Complaints - A Frequent
4
5 Symptom Reported by Patients with Subjective Cognitive Decline, Mild Cognitive
6
7 Impairment and Alzheimer's Disease. *Curr Alzheimer Res* 2018;15(3):219–228. doi:
8
9 10.2174/1567205014666171120145349
10
11
12 51. Parizkova M, Lerch O, Moffat SD, et al. The effect of Alzheimer's disease on spatial
13
14 navigation strategies. *Neurobiol Aging* 2018; 64:107-115. doi:
15
16 10.1016/j.neurobiolaging.2017.12.019
17
18 52. Mokrisova I, Laczó J, Andel R, et al. Real-space path integration is impaired in
19
20 Alzheimer's disease and mild cognitive impairment. *Behav Brain Res* 2016;307:150–158. doi:
21
22 10.1016/j.bbr.2016.03.052
23
24 53. Laczó J, Andel R, Nedelska Z, et al. Exploring the contribution of spatial navigation to
25
26 cognitive functioning in older adults. *Neurobiol Aging* 2017;51:67–70. doi:
27
28 10.1016/j.neurobiolaging.2016.12.003
29
30
31 54. Hort J, Andel R, Mokrisova I, et al. Effect of Donepezil in Alzheimer Disease Can Be
32
33 Measured by a Computerized Human Analog of the Morris Water Maze. *Neurodegener Dis*
34
35 2014;13(2–3):192–196. doi: 10.1159/000355517
36
37
38 55. Wu YF, Wu WB, Liu QP, et al. Presence of lacunar infarctions is associated with the
39
40 spatial navigation impairment in patients with mild cognitive impairment: a DTI study.
41
42 *Oncotarget* 2016;7(48):78310-78319. doi: 10.18632/oncotarget.13409.
43
44
45 56. Cerman J, Laczó J, Vyhnalek M, et al. Differences in spatial navigation impairment in
46
47 neurodegenerative dementias. *Cesk. Slov. Neurol* 2014 N; 77/110 (4): 449–455.
48
49
50 57. Laczó J, Andel R, Vyhnalek M, et al. APOE and spatial navigation in amnesic MCI:
51
52 results from a computer-based test. *Neuropsychology* 2014;28(5):676–684. doi:
53
54 10.1037/neu0000072
55
56
57
58
59
60


- 1
2
3 58. Laczó J, Andel R, Vyhnaček M, et al. The effect of TOMM40 on spatial navigation in
4
5 amnesic mild cognitive impairment. *Neurobiol Aging* 2015;36(6):2024–2033. doi:
6
7 10.1016/j.neurobiolaging.2015.03.004
8
9
10 59. Parizková M, Andel R, Lerch O, et al. Homocysteine and Real-Space Navigation
11
12 Performance among Non-Demented Older Adults. *J Alzheimers Dis* 2017;55(3):951–964. doi:
13
14 10.3233/JAD-160667
15
16
17 60. Vyhnaček M, Nikolai T, Andel R, et al. Neuropsychological Correlates of Hippocampal
18
19 Atrophy in Memory Testing in Nondemented Older Adults. *J Alzheimers Dis* 2014;42(3):81–
20
21 90. doi: 10.3233/JAD-132642
22
23
24 61. Sheardová K, Nedelská Z, Šumec R, et al. The effect of spiritual well-being
25
26 (transcendental and non-transcendental domain) on regional brain atrophy in non-demented
27
28 subjects with memory complaints: 3-year follow up data from the Czech Brain Aging Study
29
30 [abstract]. *Alzheimers Dement* 2018; 14(Suppl 7):P587–P588. doi:
31
32 <https://doi.org/10.1016/j.jalz.2018.06.654>
33
34
35 62. Chantí-Ketterl M, Andel R, Lerch O, et al. Cholesterol and cognitive performance among
36
37 community volunteers from the Czech Republic. *Int Psychogeriatr* 2015;27(12):2087–2095.
38
39 doi: 10.1017/S1041610215000320
40
41
42 63. Pappas C, Small BJ, Andel R, et al. Blood Glucose Levels May Exacerbate Executive
43
44 Function Deficits in Older Adults with Cognitive Impairment. *J Alzheimers Dis* 2019;
45
46 67(1):81–89. doi: 10.3233/JAD-180693
47
48
49 64. Šumec R, Sheardová K, Marciniak R, et al. Meditation's impact on cognitive functions in
50
51 mild cognitive impairment: A pilot study. *Biomed Pap Med Fac Univ Palacký Olomouc*
52
53 *Czech Repub* 2017;161(1):54–56.
54
55
56
57
58
59
60

- 1
2
3 65. Tillmann T, Pikhart H, Peasey A, et al. Psychosocial and socioeconomic determinants of
4 cardiovascular mortality in Eastern Europe: A multicentre prospective cohort study. *PLoS*
5
6 *Med* 2017;14(12):e1002459. doi: 10.1371/journal.pmed.1002459
7
8
9
10 66. Brayne C, Davis D. Making Alzheimer's and dementia research fit for populations. *Lancet*
11
12 2012;380(9851):1441–1443. doi: 10.1016/S0140-6736(12)61803-0.
13
14 67. Sachdev PS, Lipnicki DM, Kochan NA, et al. The Prevalence of Mild Cognitive
15
16 Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration.
17
18 *PLoS One* 2015;10(11):e0142388. doi: 10.1371/journal.pone.0142388
19
20
21

22 **Figure legends:**

23
24 Figure 1 The frequency of vascular risk factors in CBAS cohort
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Vascular risk factors frequency in CBAS cohort (%)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

STROBE (Strengthening The Reporting of OBServational Studies in Epidemiology) Checklist

A checklist of items that should be included in reports of observational studies. You must report the page number in your manuscript where you consider each of the items listed in this checklist. If you have not included this information, either revise your manuscript accordingly before submitting or note N/A.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

Section and Item	Item No.	Recommendation	Reported on Page No.
Title and Abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	
Introduction			
Background/Rationale	2	Explain the scientific background and rationale for the investigation being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	
Methods			
Study Design	4	Present key elements of study design early in the paper	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	

Section and Item	Item No.	Recommendation	Reported on Page No.
Data Sources/ Measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	
Study Size	10	Explain how the study size was arrived at	
Quantitative Variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical Methods	12	(a) Describe all statistical methods, including those used to control for confounding	
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive Data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome Data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	

Section and Item	Item No.	Recommendation	Reported on Page No.
Main Results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other Analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
Discussion			
Key Results	18	Summarise key results with reference to study objectives	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	
Other Information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Once you have completed this checklist, please save a copy and upload it as part of your submission. DO NOT include this checklist as part of the main manuscript document. It must be uploaded as a separate file.